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Abstract 
The overall goal of this thesis was to understand the mechanisms underlying -
adrenergic receptor (-AR) regulation of anion secretion and epithelial cell 
migration on mucociliary clearance and epithelial repair in human airways. The 
first chapter of the thesis presents an overview of the literature with the purpose 
of providing background information of mucociliary clearance, airway epithelial 
cell restitution and specific inflammatory disease conditions where these 
processes contribute to the innate defense of the airways. Chapters 2 and 3 
describe the methods, results and a discussion of experiments that were 
performed to address the overall goal of the thesis. The final chapter presents a 
general discussion of the major findings of these studies in the context of what is 
presently known about the role of -AR regulation of epithelial function in 
airways.   
 Initial experiments presented in Chapter 2 so looked at the effects of 
growth conditions on -AR localization in a human airway epithelial cell model 
system (Calu-3 cells). The results from these experiments showed that under air-
liquid interface (ALI) conditions basolateral stimulation with 1M epinephrine 
produced a significant increase in CFTR dependent anion secretion, whereas 
cells that were grown under liquid liquid interface (LLI) had a much smaller 
increase secretion when stimulated with the same concentration of epinephrine. 
These results indicated that basolateral expression of -ARs is increased when 
cells were grown under ALI. Furthermore Calu-3 cells that were apically 
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stimulated with the 2-AR selective agonist salbutamol produced an increase in 
anion secretion similar to what was observed with 8cpt-cAMP, a non-
metabolizable analog of cyclic AMP. Additionally, when cells were treated with 
carvedilol, an inverse agonist acting at 2-ARs, an initial decrease in basal Isc 
occurred and carvedilol treatment after stimulation with 8cpt-cAMP inhibited 
anion secretion. Cells pretreated with nocotazole, an agent that disrupts 
microtubule assembly, blocked the inhibitory effects of carvedilol on anion 
secretion, suggesting that endocytosis was necessary in order to observe the 
inhibitory effects of carvedilol. Finally, western blot analysis of apical membrane 
proteins showed that when cells were treated with carvedilol there was reduced 
expression of CFTR in the apical membrane, which was not observed following 
stimulation with epinephrine. 
 Experiments in chapter 3 were designed to investigate the effects of -AR 
agonists on epithelial cell migration. Stimulation of Normal Human Bronchial 
Epithelial (NHBE) cells and Calu-3 cells), with a 2-AR agonist produced a 
significant increase in time to wound closure compared to untreated control cells. 
Moreover, agonist stimulated cells were rescued when pretreated with -AR 
antagonists propranolol or ICI-118551. The addition of -AR agonists 
epinephrine or salbutamol to CFTR silenced cells (shCFTR) or cells where CFTR 
was inhibited with 20M CFTRinh-172 showed no further decrease in migration 
rate suggesting that inhibition due to a change in CFTR expression or activity. 
Furthermore -AR agonists reduced lamellipodia protrusion similar to what was 
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observed after CFTR inhibition. Overall these results suggest that treatment of 
airway epithelial cells with -AR agonists causes a decrease in migration rate 
leading to a significant reduction in the time required for complete wound closure. 
Additionally these results suggest that stimulating cells with carvedilol causes 
inhibition of cAMP-stimulated anion secretion by promoting retrieval and 
internalization of CFTR from the apical membrane. These results signify that the 
chronic use of -AR agonists can lead to increased risk for infection in individuals 
with obstructive airway disease and the use of bias ligands that promote Gs 
signaling while blocking -arrestin signaling may be the key to effectively treating 
these patients. These drugs would potentially promote wound repair and 
mucociliary clearance while limiting the risk of increased exacerbations and 
infection  
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A. Introduction 
1. Anatomical Considerations 
 The respiratory system is composed of upper and lower airways that make 
up most of the dead space volume within the lung. The upper airways include the 
nose, mouth, pharynx and larynx, which serve to warm and moisten the inhaled 
air before reaching the trachea (Martin, Frija, Burgel 2013; Strohl, Butler, 
Malhotra 2012) The lower airways are composed of the trachea, bronchi, 
bronchioles and alveoli (Martin, Frija, Burgel 2013; Strohl, Butler, Malhotra 2012). 
Both components are important in the process of respiration, however in this 
thesis the focus will be on the lower airways. The lower airways can be 
categorized into two zones. The conducting zone, consisting of the trachea 
bronchi and bronchioles, and the respiratory zone made up of the alveoli (Rock 
2014). The epithelium of the conducting airways is essential in removal of 
inspired foreign material, wound repair and innate immune defense against 
microbial infection. The major cell types that make up the epithelium within the 
conducting airways are basal cells, ciliated cells, goblet cells, Clara cells and 
neuroendocrine cells which form a pseudostratified epithelium (Hackett et al. 
2011; Hajj et al. 2007a; Hajj et al. 2007b; Rackley and Stripp 2012; Roomans 
2010; Yang and Chen 2014). There are two main cells types that have the ability 
to differentiate and repair the epithelium after epithelial damage. These cells are 
basal cells and Clara cells (Crystal et al. 2008; Rackley and Stripp 2012). Basal 
cells are progenitor cells that can differentiate into both ciliated and goblet cells 
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where Clara cells are secretory cells that can differentiate into ciliated cells or 
divide to form new Clara cells (Rackley and Stripp 2012). As one moves down 
the airways, the number of goblet cells declines and Clara cells become more 
dominant. This is one of the landmarks for the transition from cartilaginous upper 
bronchi to the terminal distal bronchioles (Crystal et al. 2008; Davis and Dickey 
2008; Rackley and Stripp 2012).   
 The respiratory zone of the lower airways is primarily responsible for gas 
exchange. The major epithelial cell types located in this region include Clara 
cells, alveolar type I and alveolar type II cells (Matthay, Robriquet, Fang 2005; 
Rackley and Stripp 2012). Alveolar type I cells are responsible for the gas 
exchange process and also play a role in alveolar fluid reabsorption (Matthay, 
Robriquet, Fang 2005; Planes et al. 2010; Rawlins et al. 2008; Rawlins 2008; 
Sartori and Matthay 2002; Shabbir et al. 2013). The process of fluid reabsorption 
in the alveoli is important in new borns as well as individuals with edema (Planes 
et al. 2010; Sartori and Matthay 2002). This process is facilitated by Na+ uptake 
in the alveoli, the major player being amiloride senstive Na+ channel ENaC 
located in apical membrane (Fronius 2013; Planes et al. 2010; Shabbir et al. 
2013). The transport of Na+ creates a driving force for water to follow, causing 
excess fluid in the alveolar space to be reabsorbed (Planes et al. 2010; Sartori 
and Matthay 2002; Shabbir et al. 2013; Vadasz, Raviv, Sznajder 2007). This is 
accomplished by both ENac and the basoloateral Na+/K+ ATPase, which pumps 
out 3 Na+ for 2 K+ ions, together ENaC and Na+/K+ ATPase create the needed 
driving force to allow fluid to be reabsorbed in the alveoli (Fronius 2013; Vadasz, 
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Raviv, Sznajder 2007). Alveolar type II cells are known to secrete surfactant as 
well as transport Na+ and Cl- out of the alveolar lumen, producing a driving force 
for fluid absorption. This helps to eliminate fluid within the alveolar space, which 
occurs as a result of the hydrostatic pressure within the alveolar capillaries and 
under conditions of lung injury (Matthay, Robriquet, Fang 2005).The alveolar type 
II cells are also thought to be the progenitor cells in the lower lung giving rise to 
both alveolar type I cells and alveolar type II cells (Rackley and Stripp 2012).  
2. Airway Diseases  
 Cystic Fibrosis (CF)  is a lethal congenital obstructive airway disease that 
affects 60 million people worldwide, primarily those of European decent (Guggino 
and Stanton 2006; O'Sullivan and Freedman 2009).This disease is caused by 
mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) 
gene that is located on chromosome 7, producing alterations in CFTR structure 
that lead to disruptions in Cl- channel function (Boucher 2004; Horsley and 
Siddiqui 2014; O'Sullivan and Freedman 2009). The most common mutation is 
the F508 where the phenylalanine residue at position 508 is deleted. This 
mutation causes misfolding of the CFTR protein, preventing it from trafficking 
from the endoplasmic reticulum to the apical membrane (Boucher 2004; Guggino 
and Stanton 2006; Mall et al. 2004). At this time there are more than 1500 known 
mutations in CFTR, many of which are not fully understood in the context of 
disease severity (O'Sullivan and Freedman 2009). CF affects multiple body 
systems including: reproductive, gastrointestinal, endocrine and respiratory 
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systems. However respiratory disease is the most life threatening, leading to 
infections in the airways at an early age that persist throughout life (Guggino and 
Stanton 2006; Horsley and Siddiqui 2014; O'Sullivan and Freedman 2009). 
 CFTR is an essential ion channel responsible for Cl- secretion. In addition 
there is evidence that it also regulates the function of epithelial Na+ channels 
(ENaC) that are also localized in the apical membrane of airway epithelial cells. 
(Chmiel and Davis 2003; Guggino and Stanton 2006). In CF patients where 
CFTR is either not functioning or is not present in the apical membrane, an 
increase in ENaC-dependent Na+ absorption occurs which leads to a decrease in 
the level of fluid on the airway surface. This reduction in the pericilliary liquid 
layer (PCL) reduces mucociliary clearance, a process responsible for the 
transportation of mucus and entrapped foreign material out of the airways 
(Boucher 2004; Chmiel and Davis 2003; Grasemann and Ratjen 2013; Guggino 
and Stanton 2006; Horsley and Siddiqui 2014). The decrease in fluid secretion 
coupled with increased Na+ and fluid absorption alters the consistency of mucus, 
causing it to become dehydrated with increased viscosity and greater adherence 
to the airway surface. (Berdiev, Qadri, Benos 2009). A diminished PCL causes 
ciliary dysfunction, preventing the cilia from beating properly. This prevents the 
movement of mucus out of the lung, leading to mucus plugs, which cause airway 
obstruction, as well as increasing the risk of infection and airway disease 
(Boucher 2004; Chmiel and Davis 2003; Horsley and Siddiqui 2014). A more 
detailed discussion of the cellular and molecular mechanisms that underlie 
mucociliary clearance is presented later in this review. 
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 Bronchodilators mainly 2-AR agonists are a form of therapy in individuals 
with CF often used alongside chest physiotherapy (Hordvik et al. 1999; Salvatore 
and D'Andria 2002). These drugs help relieve symptoms such as wheezing and 
shortness of breath and aid in the clearing of airway obstructions created from 
excess mucus build up and epithelial cell damage (Halfhide, Evans, Couriel 
2005; Hordvik et al. 1999; Salvatore and D'Andria 2002). Although the use of 2-
AR agonists remains controversial there have been several studies have shown 
that they can be beneficial for CF patients (Cropp 1996; Halfhide, Evans, Couriel 
2005; Hordvik et al. 1999; Kent et al. 2014; Salvatore and D'Andria 2002). It has 
been shown that both short acting (albuterol) and long acting (salmeterol) 2-AR 
agonists help to increase lung function (Halfhide, Evans, Couriel 2005; Kent et al. 
2014; Salvatore and D'Andria 2002). These agents promote the dilation of the 
airways by acting on smooth muscle and enhancing mucociliary clearance by 
increasing ciliary beat frequency of the airway epithelium (Bennett 2002; Cazzola 
and Matera 2014; Cropp 1996; Salathe 2002; Ulrik 2014). Both of these 
mechanisms help to increase airflow and reduce obstructions in the airway 
allowing for symptom relief (Halfhide, Evans, Couriel 2005). 
 Inflammation occurs early in patients with CF leading to increased risk to 
infection as well as future airway damage (Balfour-Lynn and Welch 2012; Chmiel 
and Konstan 2007; Nichols, Konstan, Chmiel 2008). Glucocorticoids delivered as 
inhaled corticosteroids (ICS), are a form of therapy used in CF patients to 
decrease inflammation, mucus production, edema formation and bronchial 
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hyperactivity (Balfour-Lynn and Welch 2012; Chmiel and Konstan 2007; Nichols, 
Konstan, Chmiel 2008). Glucocorticoids have also been shown to slow the 
progress of CF disease on the airways, especially in children treated with these 
medications (Balfour-Lynn and Welch 2012; Cheng, Ashby, Smyth 2013). The 
use of glucocorticoids can lead to a decrease in airway inflammation in these 
patients, however improvements in overall lung function are often minimal and 
further research is needed (Balfour-Lynn and Welch 2012). The chronic use of 
glucocorticoids does not come without risk and can lead to negative effects on 
growth,  metabolic disease and osteoporosis (Chmiel and Konstan 2007; Nichols, 
Konstan, Chmiel 2008). 
 Chronic Obstructive Pulmonary Disease (COPD) is another common 
airway disease that is characterized by airway obstruction produced by chronic 
inflammation leading to increased dyspnea, coughing and sputum production 
over time (Aaron 2014; Qureshi, Sharafkhaneh, Hanania 2014). COPD affects 
about 24 million people in the United States and about 120,000 deaths per year 
(Qureshi, Sharafkhaneh, Hanania 2014). People that suffer from COPD have 
chronic inflammation and are highly sensitive to viral, bacterial and other 
particulates from the environment that lead to exacerbation of symptoms 
(Qureshi, Sharafkhaneh, Hanania 2014). These exacerbations trigger an immune 
response which results in increased mucus production and emphysema onset 
(Aaron 2014; Martin, Frija, Burgel 2013). People with COPD suffer damage to the 
small airways which are due to an abnormal epithelium caused by repeated 
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encounters with cigarette smoke, dust, or fumes and the need for the airway 
epithelium to repair itself (Martin, Frija, Burgel 2013; Qureshi, Sharafkhaneh, 
Hanania 2014; Rab et al. 2013). This damaged epithelium leads to narrowed 
airways and increased mucus both contributing to the obstructive nature of this 
disease (Qureshi, Sharafkhaneh, Hanania 2014). Furthermore the onset of 
emphysema in COPD patients is thought to be due to the continual infammatory 
episodes that are attributed to this disease (Aaron 2014; Martin, Frija, Burgel 
2013). These exacerbations lead to terminal bronchiole destruction causing 
decreased support and the collapse of alveolar walls (Martin, Frija, Burgel 2013). 
 Persons that suffer from COPD have similar airway problems as those 
that suffer from CF; these include defects in mucocilary clearance which include 
decreased PCL inhibiting ciliary movement and leading to decreased clearance 
of debris, bacteria and other foreign materials in the airways (Cantin et al. 2006; 
Rab et al. 2013). This leads to increased risk of infection (Rab et al. 2013). 
Furthermore COPD leads to increased inflammatory response due to higher rate 
of infection in the lungs similar to what is seen in CF (Rab et al. 2013). All of 
these symptoms in COPD are due to the loss of CFTR function, unlike CF 
patients that have limited CFTR function or limited CFTR in the membrane (Rab 
et al. 2013). The loss of CFTR function in COPD is thought to be due to the 
inhalation of toxic chemicals like cigarette smoke which have shown to have a 
negative impact on anion secretion in the airways, which is essential for proper 
lung function and the ability to maintain a healthy airway (Cantin et al. 2006; Rab 
et al. 2013). 
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 Individuals with COPD take bronchiodialators to help open the airways to 
allow for maximum airflow (Baker et al. 2014; Qureshi, Sharafkhaneh, Hanania 
2014). Short acting 2-AR agonists like albuterol are used in these patients to 
help control exacerbations (Qureshi, Sharafkhaneh, Hanania 2014). However the 
use of long acting 2-AR agonists like formoterol or salmeterol have also been 
shown to decrease exacerbations (Baker et al. 2014; Nardini et al. 2014; 
Qureshi, Sharafkhaneh, Hanania 2014). These drugs can produce significant 
improvement in COPD patients that take them, increasing tolerance of physical 
activity as well as over all lung function (Nardini et al. 2014). Although 2- 
agonists can be used alone to help with symptom relief, studies have shown 
pairing them with ICS improves the function of the airways in a COPD patient as 
opposed to either used alone (Kew, Dias, Cates 2014; Miller-Larsson and 
Selroos 2006). 
 The use of glucocorticoids in patients with COPD aid in decreasing the 
inflammation of the airways as well as mucus production (Ammit 2013; Balfour-
Lynn and Welch 2012; Boardman et al. 2014; Kew, Dias, Cates 2014; Nichols, 
Konstan, Chmiel 2008). These drugs are more often times paired with 2-AR 
agonists, however individuals with chronic COPD may take them as a 
monotherapy due to increased inflammation from recurrent epithelial damage 
(Ammit 2013). The use of these drugs in combination therapies allows for both 
aspects of the disease, bronchoconstriction and inflammation, to be targeted and 
corrected, evidence suggests they increase the ability for the ICS to reduce 
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inflammation (Chung, Caramori, Adcock 2009; Mansfield 2008; Miller-Larsson 
and Selroos 2006).  
 Asthma represents another obstructive airway disease that affects the 
lives of roughly 8% of adults and more than 9% of children living in the United 
States (Centers for Disease Control and Prevention (CDC) 2011; Moorman et al. 
2012). Asthmatics suffer from symptoms including chest constriction, shortness 
of breath, mucus over production, and excess coughing and wheezing (Erle and 
Sheppard 2014; Moorman et al. 2012; Walker et al. 2011). These symptoms are 
brought on by airborne irritants such as pollution, allergens, chemicals and other 
inhaled material which lead to bronchioconstriction and inflammation. Over time 
persistent asthma attacks may lead to airway remodeling (Elias et al. 1999; Erle 
and Sheppard 2014; Moorman et al. 2012). Airway remodeling occurs in 
response to chronic epithelial injury which ultimately results in airway wall 
thickening, increase in mucus secretion and changes in epithelial cell 
morphology including possible ciliary dysfunction (Erle and Sheppard 2014; 
Wasilewski, Lougheed, Fisher 2014). There is no cure for asthma but there are 
therapeutic approaches that help relieve the symptoms associated with this 
disease (Lipworth 2007; Moorman et al. 2012).  
 2-adrenergic receptor agonists are typically used to control asthma 
symptoms because of their ability to induce airway smooth muscle relaxation, 
promote mucus clearance and increase airflow (Erle and Sheppard 2014; 
Lipworth 2007; Walker et al. 2011). 2-AR agonists are the recommended 
 11 
 
treatment and a standard for treating asthmatics (Bonini et al. 2013; Clifford and 
Knox 2012). The use of short acting -agonist drugs like albuterol are the most 
common form of treatment in asthma (Xia et al. 2013). These drugs are mainly 
used by individuals with intermittent asthma and are to be used occasionally 
when an asthmatic episode occurs (Xia et al. 2013) however long acting 2-
agonists are also used in people that suffer from asthma. These drugs are 
prescribed to help in the maintenance of those who have recurrent episodes of 
wheezing, shortness of breath or chest tightness (Cates et al. 2014; Saguil and 
Garcia 2014). Long acting 2-agonists are meant to prevent asthmatic episodes 
from occurring and if one were to occur it is thought use of these drugs would 
decrease the intensity and length of the episode (Crompton 2006; Mak and 
Hanania 2012).  
 Glucocorticoids are another type of medication that are used to control 
asthma. These drugs are often used as a controller medication, reducing airway 
inflammation (Mansfield 2008). Gluocorticoids have been a standard in asthma 
treatment (Boardman et al. 2014) for short periods of time, this is due to the side 
effects these drugs can cause (Vandevyver et al. 2013). Like 2-agonists these 
drugs are usually taken through an inhaler or nebulizer (Crompton 2006). 
Glucocorticoids are often paired with 2-AR agonist providing increased symptom 
relief for the individuals that take them (Mansfield 2008; Miller-Larsson and 
Selroos 2006). The individual use of glucocorticoids are a less effective therapy 
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in asthma treatment and have major side effects (Barnes and Adcock 2009; 
Crompton 2006; Newton 2014; Roos and Nord 2012). 
3. Airway Disease Therapuetics 
 A common therapeutic strategy for the treatment of CF, COPD and 
asthma is the use of inhaled 2 receptor agonists and glucocorticoids to alleviate 
acute airway responses to airborne agents that can exacerbate inflammation and 
to minimize immunologic responses that can lead to long term damage to the 
airways. The following sections provide a brief review of the receptors and 
signaling mechanisms associated with the airway epithelium that mediate the 
response to these important therapeutic agents.     
a. Adrenergic receptor expression and signaling: 
 Adrenergic receptors expressed in the lung include both alpha () and 
beta () G-protein coupled receptor (GPCR) subtypes. Airway smooth muscle 
cells possess 1 and 2 subtypes (Barnes 1989; Goldie, Paterson, Lulich 1990). 
Stimulation of these receptors causes smooth muscle contraction that reduces 
airway caliber and airflow, however they do so through two different mechanisms 
(Goldie, Paterson, Lulich 1990). Agonist binding to the1 receptor causes 
calcium release through Gq/11 signaling (1b receptors) or through the activation 
of nifedipine-sensitive Ca2+ channels resulting in Ca2+ uptake from the 
extracellular media (a1a receptors). In contrast, 2 receptors are coupled to the Gi 
signaling cascade, causing a decrease in adenylyl cyclase activation and a 
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reduction in cyclic AMP (cAMP) (Goldie, Paterson, Lulich 1990). -receptors in 
the lung are expressed by smooth muscle cells, airway epithelial cells, sensory 
nerves, alveolar epithelial cells and immune cells (Barnes 2004). 1 and 2 
subtypes have been identified and have been shown to signal through Gs leading 
to the production of cAMP and activation of protein kinase A (PKA). 2 receptors 
are the most highly expressed in the airways (Barnes 2004). When stimulated 2 
receptors cause smooth muscle relaxation and increase airflow into the lung. 
They also increase ciliary beat frequency of ciliated epithelial cells  and an 
increase in electrolyte, fluid and mucus secretion from submucosal gland 
epithelial cells and clara cells (Barnes 2004; Goldie, Paterson, Lulich 1990; 
Shore and Moore 2003). Coupling of 2 adrenergic receptors to adenylyl cyclase 
and subsequent increases in cAMP is critical for producing the therapeutic 
benefits of 2 agonists in diseases such as CF, COPD and asthma (Bennett 
2002). The combined effects of bronchorelaxation and increased epithelial fluid 
secretion and ciliary beating serves to reduce airway obstruction and enhance 
the clearance of  mucus and potentially infectious microorganisms from the lung 
(Barnes 1995; Barnes 2004; Bennett 2002; Goldie, Paterson, Lulich 1990; Shore 
and Moore 2003).  
 As previously discussed the use of 2-AR in obstructive airway disease is 
a common form of therapy (Halfhide, Evans, Couriel 2005; Kent et al. 2014; 
Salvatore and D'Andria 2002). Common 2-agonists that are used are short 
acting agonists, albuterol or salbutamol and long acting agonists, salmeterol and 
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formeterol, all of which are used in CF, COPD and asthma (Halfhide, Evans, 
Couriel 2005; Kent et al. 2014; Salvatore and D'Andria 2002). Short acting 
agonists are mainly used for fast symptom relief. During an asthma attack or 
when individuals are having increased difficulty breathing (Paris et al. 2008; 
Qureshi, Sharafkhaneh, Hanania 2014; Xia et al. 2013). The use of long acting -
agonists is becoming more common in patients with these diseases. These 
medications like salmeterol are usually inhaled through a nebulizer and last up to 
12 hours. This allows prolonged symptom relief and is thought to decrease 
exacerbations that would warrant the use of short acting agonists (Baker et al. 
2014; Cates et al. 2014; Nardini et al. 2014; Qureshi, Sharafkhaneh, Hanania 
2014; Saguil and Garcia 2014; Tan and Corren 2014).  
 The popularity of these -AR therapeutics is unfortunately associated with 
negative consequences. The chronic use of 2-agonists leads to desensitization 
of airway smooth muscle cells in the response to a 2-agonist (Clifford and Knox 
2012). This leads to decreased effectiveness of these medications in dilating the 
airways for maximal airflow (Clifford and Knox 2012). This desensitization is 
mainly due to the down-regulation of the 2-AR receptor leading to a reduction in 
available agonist binding sites and therefore, subsequent activation of G-protein 
signaling. (Clifford and Knox 2012). This phenomenon occurs through the 
activation of -arrestin signaling pathway, a second pathway stimulated by the 
binding of a -agonist to the 2-AR. The effects of this pathway are different 
between the 1-AR and 2-AR where -arrestin has higher affinity to the 2-AR 
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verses 1-AR (Kobayashi et al. 2005; Reiter and Lefkowitz 2006; Shenoy et al. 
2006). When -ARs are stimulated, G-protein receptor kinases (GRKs) are 
activated and recruited to phosphorylate the C-terminal tail of the receptor (Ma 
and Pei 2007; Reiter and Lefkowitz 2006; Tohgo et al. 2003). The 
phosphorylated tail of the GPCR recruits and activates -arrestins leading to 
downstream signaling of desensitization (Reiter and Lefkowitz 2006; Shenoy et 
al. 2006). Once -arrestin is recruited it causes uncoupling of the GPCR by 
binding to the C-terminal tail deactivating the receptor (Kobayashi et al. 2005; Ma 
and Pei 2007; Reiter and Lefkowitz 2006; Tohgo et al. 2003). -arrestin will then 
bind clathrin which will promote the internalization process of the receptor 
through endocytosis via clathrin coated pits, promoting the desensitization 
process of the receptor (Ma and Pei 2007; Shenoy et al. 2006; Tohgo et al. 
2003). It has also been shown that -arrestin acts as a scaffold for MAPK by 
binding ERK1/2 allowing further downstream signaling in a G-Protein 
independent manner (Kobayashi et al. 2005; Reiter and Lefkowitz 2006; Shenoy 
et al. 2006; Tohgo et al. 2003). It is the combination of all these effects that 
cause the 2-AR desensitization. 
 A potential problem with certain agonists is that the receptors that are 
activated can signal through more than one pathway leading to undesirable side 
effects which often limit their therapeutic usefulness (Tilley 2011). Studies over 
the past decade have shown that structural modifications of these agonists can 
induce distinct conformational changes in the receptor. These changes can bias 
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signaling towards one pathway relative to the others so that activation of 
downstream targets that cause detrimental side effects can potentially be 
minimized (Andresen 2011; Tilley 2011). The use of bias ligands for treating 
various conditions is a fairly recent development. A bias ligand will bind to a 
GPCR, for example and activate one of two or more signaling pathways, such as 
G, while reducing the activation of the -arrestin pathway or vice versa, 
reducing the activation of G while increasing -arrestin signaling (Andresen 
2011; Strachan et al. 2014; Tilley 2011). One studied model of bias signaling is 
with the angiotension II type 1 receptor (AT1R). This GPCR promotes Gq 
activation leading to Ca2+ release and is a target for antagonists in the treatment 
of hypertension and heart failure (Tilley 2011). When a bias ligand such as 
TRV120023 (Kim et al. 2012; Monasky et al. 2013; Strachan et al. 2014; Tilley 
2011; Violin et al. 2010) binds to AT1R a conformational change in the receptor 
occurs promoting -arrestin signaling (Andresen 2011; Monasky et al. 2013; 
Strachan et al. 2014; Tilley 2011). This bias ligand produces an increased 
response to -arrestin signalling while having an equal amount of decreased 
efficacy to Gq signalling (Strachan et al. 2014; Tilley 2011). The activation of -
arrestin signaling has been shown to be beneficial in the treatment of 
hypertension and heart failure (Kim et al. 2012; Monasky et al. 2013; Tilley 
2011). One way is by blocking Gq signaling leading to a decrease in Ca
2+ 
release, which has shown to contribute to heart failure and hypertension (Kim et 
al. 2012; Monasky et al. 2013; Tilley 2011). This is done by promoting 
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desensitization of the receptor by internalization via clathrin vesicals as well as 
recrutiment of c-Src and AP-2 which play a part in receptor endocytosis. 
Furthermore it has been shown that -arrestin can increase cardioprotective 
elements, potentially by upregulating MAPK signaling which has been shown to 
reduce apoptosis in cardiac myocytes (Kim et al. 2012; Tilley 2011). TRV120023 
has also shown to increase cardiomyocyte contractility although the exact 
mechanism on how this effect is produced is still unclear (Strachan et al. 2014; 
Tilley 2011). Evidence however shows that this may be due to the ligands effects 
on dephosphorylation of certain proteins which lead to an increase in 
myofilaments response to Ca2+ (Monasky et al. 2013). 
 Another receptor that has been studied using bias agonism is the 1 
parathyroid hormone receptor (PTH1R) which plays an important role in bone 
formation and kidney function (Appleton et al. 2013; Gesty-Palmer and Luttrell 
2011). This is a GPCR that activates Gs and Gq signaling. The activation of 
PTH1R produces bone formation by stimulating osteoblasts as well as causing 
bone reabsorption via the activation of osteoclasts (Bohinc and Gesty-Palmer 
2013; Ferrari and Bouxsein 2009; Gesty-Palmer and Luttrell 2011). Agonists of 
PTH1R are used in medicine for patients with osteoporosis, which is a disease 
that causes a decreased bone mass causing bones to become weak (Bohinc and 
Gesty-Palmer 2013; Ferrari and Bouxsein 2009; Gesty-Palmer et al. 2009; 
Gesty-Palmer and Luttrell 2011). These medications are used because they 
stimulate bone formation overall, however they do cause bone reabsorption 
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which poses a problem (Ferrari and Bouxsein 2009). Studies have shown that -
arrestin signaling plays an essential part in the process of net bone formation 
(Bohinc and Gesty-Palmer 2013; Ferrari and Bouxsein 2009; Gesty-Palmer et al. 
2009). The use of -arrestin-targeting bias ligands on PTH1R mediated effects 
on bone formation have been studied and have shown to increase bone 
formation in mice while preventing bone reabsorption, having potential in the 
treatment or prevention of osteoporosis (Gesty-Palmer and Luttrell 2011). The -
arrestin signaling pathway promotes a net gain in bone formation after PTH1R 
stimulation with an agonist because it causes inhibition of G-Protein signaling as 
well as initiating PTH1R desensitization (Gesty-Palmer and Luttrell 2011). -
arrestin bias ligands that bind to the PTH1R are thought to uncouple the PTH 
bone formation effects from its effects on bone reabsorption, however more 
research is needed to determine the mechanism of these effects in bone  (Bohinc 
and Gesty-Palmer 2013; Gesty-Palmer and Luttrell 2011). 
 Although the role of bias ligands on the AT1R and PTH1R for treating 
diseases such as hypertension and osteoporosis are still being studied, there is a 
common biased ligand used in the treatment of heart failure. This bias ligand is a 
2-AR ligand called carvedilol. Carvedilol is a -blocker that prevents the 
recycling of the receptors (Doughty and White 2007; Keating and Jarvis 2003; 
Kveiborg et al. 2007). When carvedilol blocks 2-AR signaling it prevents 
norepinephrine (NE) release, decreasing 1-AR activation and allowing for a 
decrease in heart rate thereby reducing the workload for the cardiac muscle 
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(Kaye et al. 2001; Kveiborg et al. 2007). Carvedilol also blocks 1-AR producing 
vasodilatation, again reducing the work of the heart and decreasing hypertension 
(Book 2002; Doughty and White 2007; Feuerstein and Ruffolo 1996; Keating and 
Jarvis 2003; Kveiborg et al. 2007). This ligand also prevents the formation of 
oxygen radicals and the depletion of antioxidants, which leads to a decrease in 
inflammation; an effect not seen with other -blockers (Book 2002; Doughty and 
White 2007; Kaye et al. 2001; Keating and Jarvis 2003; Kveiborg et al. 2007). 
Although not everything is known about carvedilol's mechanism(s) of action, the 
use of it in the treatment of chronic heart failure and hypertension has shown to 
be highly beneficial (Book 2002; Doughty and White 2007; Kaye et al. 2001; 
Keating and Jarvis 2003; Kveiborg et al. 2007).   
 
b. Glucocorticoid receptors: 
 Glucocorticoid receptors are another receptor found in the human airways. 
These receptors are highly concentrated in lung endothelial and epithelial cells 
(Barnes 2004). Glucocorticoid receptors help regulate inflammatory gene 
expression by producing a decrease in inflammatory cells leading to an overall 
reduction in inflammation (Barnes 2004; Ito, Getting, Charron 2006; Roos and 
Nord 2012; Schwiebert, Stellato, Schleimer 1996). These receptors are in the 
nuclear receptor subfamily of transcription factors and are also known as 
NR3C1(Boardman et al. 2014; Chung, Caramori, Adcock 2009; Vandevyver et al. 
2013). This receptor is composed of three domains, a C-terminal ligand binding 
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domain, DNA binding domain and an N-terminal domain, all three domains play 
an important role in the signaling of the receptor (Boardman et al. 2014; Nixon, 
Andrew, Chapman 2013; Vandevyver et al. 2013). When a ligand binds to the C-
terminal domain the receptor undergoes a conformational change which causes 
it to be translocated to the nucleus where it mediates gene regulation (Boardman 
et al. 2014; Nixon, Andrew, Chapman 2013; Vandevyver et al. 2013). One way 
this receptor regulates gene expression is by binding to to glucocorticoid 
response elements (GREs), sites on the promoter region of genes, which initiate 
recruitment of 'activator' or 'repressor' molecules that target transcription (Ammit 
2013; Boardman et al. 2014; Nixon, Andrew, Chapman 2013; Vandevyver et al. 
2013). The activators lead to increased gene expression of anti-inflammatory 
proteins like IL-10, where the repressors lead to down regulation of pro-
inflammatory cytokines such as IL-8 (Boardman et al. 2014). The repression of 
gene expression is also accomplished through a process called transrepression. 
This is where the glucocorticoid receptor binds directly to a transcription factor 
such as nuclear factor-B (NF-B) (a pro-inflammatory transcription factor), 
acting like an antagonist which interferes with the activation of NF-B leading to 
inhibition of transcription of proinflammatory cytokines like IL-1 (Boardman et al. 
2014; Nixon, Andrew, Chapman 2013). The inhibition of transcription can also 
occur through the inhibition of histone acetylases and recruitment of histone 
deacetylaces both of which cause negative effects on chromatin (Ammit 2013; 
Boardman et al. 2014). Through these mechanisms glucocorticoid receptor is 
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able to reduce inflammation and is utilized to treat diseases such as inflammatory 
bowel and obstructive airway diseases such as asthma and COPD (Ammit 2013; 
Boardman et al. 2014). 
4. Mucociliary Clearance  
 Ion transport by the ciliated cells of the airway surface epithelium is 
essential for establishing appropriate osmotic driving forces for the fluid transport 
required in the mucociliary clearance process. The airway surface liquid (ASL) 
consists of two phases: the periciliary liquid phase which ensures the movement 
of cilia, and the mucus phase that is layered on top of the periciliary liquid which 
is important in trapping foreign materials such as bacteria, dust, and a variety of 
airborne allergins (Knowles and Boucher 2002; Rackley and Stripp 2012; 
Toczylowska-Maminska and Dolowy 2012). The ASL allows the removal of these 
materials from the lungs through the mouth and esophagus (Rackley and Stripp 
2012; Toczylowska-Maminska and Dolowy 2012). Ion transport by the surface 
epithelium involves the regulation of electrogenic Na+ absorption and anion 
secretion. The mechanism of anion transport involves several different ion 
channels and transporters that function in a coordinated manner to produce Cl- or 
HCO3
-. Secretion in the standard model, Cl- is loaded into the cell via a 
Na+/K+/2Cl- (NKCC1) transporter located in the basolateral membrane. Chloride 
exists the cell by way of CFTR, the cAMP and ATP regulated anion channel that 
is defective in CF and/or TMEM16a, a 4,4'-diisothiocyanostilbene-2,2'-
disulphonic acid (DIDS) sensitive anion channel that is activated by increases in 
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intracellular [Ca2+] (Ballard and Spadafora 2007; Gianotti et al. 2013). The Na+/K+ 
ATPase is located on the basolateral membrane which serves to maintain Na+ 
and K+ ion gradients across the plasma membrane and contributes to the resting 
membrane potential of the cell. The Na+/K+ ATPase brings in 2K+ for every 3Na+ 
pumped out of the cell. The K+ that enters the cell as a result of Na+/K+ ATPase 
and NKCC1 activity is then recycled via specific K+ channel subtypes such as 
Kv7.1/MiRP2 (KCNQ1/KCNE3) or KCa3.1 (KCNN4) depending on whether anion 
secretion was stimulated by increases in cAMP or [Ca2+] respectively (Cotton 
2000). The increase in basolateral K+ efflux functions as a mechanism for charge 
compensation to maintain the driving force for apical secretion and the steady-
state [K+] gradient across the membrane (Bleich and Shan 2007; Cotton 2000; 
Palmer et al. 2006). The apical efflux of Cl- along with K+ exit at the basolateral 
membrane promotes paracellular Na+ transport through tight junctions between 
the epithelial cells, resulting in net transepithelial NaCl secretion under 
physiological conditions (Frizzell and Hanrahan 2012).  
 Another aspect of ion transport that is essential for mucociliary clearance 
is the process of Na+ absorption. Na+ transport is primarily dependent on apical 
ENaC (Al-Alawi et al. 2014; Caci et al. 2009; Gianotti et al. 2013). The Na+ that is 
transported across the apical membrane is pumped out of the cell across the 
basolateral membrane by the Na+/K+ ATPase. K+ ions taken up by the pump are 
recycled across the basolateral membrane through K+ channels, which helps to 
sustain the driving force for Na+ uptake. Na+ absorption by this mechanism 
produces a basolaterally positive transepithelial potential difference which serves 
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as a driving force for the paracellular movement of anions (primarily Cl-) from the 
airway lumen into the extracellular fluid (Gianotti et al. 2013). The absorption of 
NaCl sets up an important osmotic driving force fluid absorption. A balance in the 
rates of fluid absorption and secretion sets the depth of the periciliary liquid 
phase so that it matches the height of the cilia. This ensures that the mucus 
phase does not compress the cilia and restrict their movement, which occurs 
when the rate of fluid absorption is enhanced as in CF (Al-Alawi et al. 2014; Caci 
et al. 2009; Gianotti et al. 2013). A model summarizing the mechanisms of Na+ 
absorption and anion secretion is presented in Figure 1. 
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Figure 1 
 
Figure 1: Model illustrating the essential channels needed for the process of mucocilliary 
clearance in airway epithelial cells. Epithelial Na
+ 
Channel (ENaC) absorbs Na
+
 across the 
apical membrane which is pumped out of the cell across the basolateral membrane by the 
Na
+
/K
+
 ATPase. K
+
 ions taken up by the pump are recycled across the basolateral membrane 
through K
+
 channels, which helps to sustain the driving force for Na
+
 absorption and Cl
-
 
secretion. The NKCC1 loads K
+
, Na
+
 and 2Cl
-
 into the cell. The Cl
-
 exits primarily through 
CFTR across the apical membrane. It is through the coordinated actions of these ion 
channels that regulates the depth of the PCL important in facilitating mucociliary clearance.  
  
 Na+ absorption is highly regulated by CFTR (Berdiev, Qadri, Benos 2009; 
Mall 2008; Reddy and Quinton 2003; Toczylowska-Maminska and Dolowy 2012). 
When CFTR is activated transport of Na+ into the cell by ENaC is decreased and 
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when CFTR is not activated apical Na+ absorption occurs (Berdiev, Qadri, Benos 
2009; Kunzelmann and Mall 2001; Mall 2008; Reddy and Quinton 2003). These 
mechanisms of fluid secretion and absorption are thought to be due to the 
coupling behavior of CFTR and ENaC (Berdiev, Qadri, Benos 2009; Varelogianni 
et al. 2013). Although this coupling behavior is not fully understood it is 
suggested that CFTR and ENaC are located near each other in the apical 
membrane potentially forming a complex that allows these two proteins to 
interact directly (Berdiev, Qadri, Benos 2009).  
 
Cell Migration 
 The process of cell migration in the airways is another essential process 
after injury occurs. The process of cell migration involves four main steps; 
polarization, protrusion, adhesion/traction and finally retraction. This first step of 
polarization is regulated strongly by chemotaxis elements that allow for the cell to 
form a leading (front end) and trailing edge (rear end) allowing migration to occur 
(Ridley et al. 2003; Schwab et al. 2012) This is driven by Rho Family GTPases 
like division control protein 42 (Cdc42), an essential player in the polarization of 
cells by contributing to localization of organelles and the microtubule-organizing 
center (MTOC) (Ridley et al. 2003; Schwab et al. 2012). Polarization of cells 
promotes cell protrusion at the front of the cell (Ridley et al. 2003; Roca-
Cusachs, Sunyer, Trepat 2013). These protrusions are called filapodia which are 
long thin extensions of the cell consisting of a barbed end and a pointed end 
forming long bundles made of actin that act as sensors, or lamellipodia which are 
 26 
 
larger and wider extensions created by branching polymerized actin filaments 
that are responsible for the migratory process and forward movement of cells 
(Ridley et al. 2003; Schwab et al. 2012; Vicente-Manzanares, Webb, Horwitz 
2005). During migration cells adhere to the extra cellular matrix to promote 
satiability and forward movement. This is mediated by myosin II, which interacts 
with actin filaments creating traction for the migrating cells, and integrin 
adhesions acting as anchors at the protruding end of cells allowing forward 
movement (Ridley et al. 2003). The turnover of integrins is essential in the 
process of migration. After forward movement occurs adhesions reassemble to 
the ECM, aiding in traction, and disassemble from the trailing end which allows 
continual forward movements (Ridley et al. 2003; Schwab et al. 2012) The 
disassembly of actin from the trailing end marks the final step in migration, 
retraction (Ridley et al. 2003; Vicente-Manzanares, Webb, Horwitz 2005). Myosin 
II is also involved in rear end detachment of the migrating cells. This is needed to 
create tension between the integrins/adhesions and the retraction of the tail end 
of the cell (Ridley et al. 2003; Vicente-Manzanares, Webb, Horwitz 2005). These 
four steps ensure that the process of wound repair is accomplished and that cells 
migrate as a single unit to repair the damaged epithelium (Schiller, Maniak, 
O'Grady 2010; Wang et al. 2003; Zhao et al. 1996a).  
 Extracellular signal-related kinase (ERK)/ mitogen activate protein kinase 
(MAPK) are major players in the migratory process of keratinocytes and corneal 
epithelial cells. Increasing ERK and or MAPK activity promotes cell migration and 
proliferation (Lu, Reinach, Kao 2001; Pullar, Chen, Isseroff 2003; Wang et al. 
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2003). However it has been shown that 2-AR also plays a role in the regulation 
of cell migration in these cells (Chen, Hoffman, Isseroff 2002; Ghoghawala et al. 
2008; Pullar, Chen, Isseroff 2003). When 2-AR is stimulated with an agonist, like 
epinephrine, the migration rate is significantly reduced, but when stimulated with 
an antagonist the opposite effect occurs, an increase in the migration rate is 
observed (Chen, Hoffman, Isseroff 2002; Ghoghawala et al. 2008; Pullar, Chen, 
Isseroff 2003; Pullar et al. 2006; Pullar et al. 2012). It has been shown in 
subsequent studies that 2-AR stimulates the activity of protein phosphatase 2A, 
a serine/threonine phosphatase that can dephosphorylate ERK, therefore 
reducing the stimulatory effect of ERK on migration (Pullar, Chen, Isseroff 2003; 
Pullar et al. 2006). In contrast, 2-AR antagonists prevent PP2a activation thus 
promoting cell migration. Thus the results from these experiments provided 
insight as to the identity of the signaling pathway that links 2-AR activation to a 
reduction in the rate of cell migration (Ghoghawala et al. 2008; Pullar, Rizzo, 
Isseroff 2006; Pullar et al. 2007). 
 Another major contributor to cell migration are guidance cues cells use to 
aid in the process of migration (Roca-Cusachs, Sunyer, Trepat 2013; Zhao et al. 
1996a). These cues involve gradients and forces of the ECM and intercellular 
matrix. Some of these cues include chemotaxis, the response to a chemical 
stimulus, mechanotaxis, the response to physical force at cell to cell or cell to 
ECM level, durotaxis, cells response to ECM stiffness and electrotaxis, the cells 
response to an electrical field (EF) (Reid and Zhao 2014; Roca-Cusachs, Sunyer, 
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Trepat 2013; Zhao et al. 1996a). For this study we will focus on the effects of 
electrotaxis in epithelial cell migration.  
 Studies done in corneal epithelial cells, keratinocytes and airway epithelial 
cells have shown that when the epithelium is wounded, a lateral current can be 
detected that establishes a local electric field (EF) that can be sensed by 
epithelial cells (Reid and Zhao 2014; Song et al. 2007; Sun et al. 2011; Zhao et 
al. 1996b). This occurs because the Transepithelial potential (TEP) of the 
epithelial layer is destroyed due to wounding (Reid and Zhao 2014; Sun et al. 
2011). During this process the cells at the wounded edge align themselves 
perpendicular to the EF and migrate toward the cathode located at the center of 
the wound (see figure 2). This type of directed migration where the EF serves as 
a guidance cue is called electrotaxis (Reid and Zhao 2014; Song et al. 2007; Sun 
et al. 2011; Wang et al. 2003; Zhao et al. 1996a; Zhao et al. 1996b). The EF also 
contributes to the reorientation of growth factor and chemosensory receptors as 
well as cytoskeleton elements towards the front (leading edge) of the cells 
located at the wounds edge, (Zhao et al. 1996a; Zhao et al. 1996b) promoting 
actin polymerization which facilitates lamellipodia protrusion and cell migration 
(Song et al. 2002; Zhao et al. 1996a; Zhao et al. 1996b).These changes in the 
receptor concentration at the leading edge of the cells allow for detection of 
growth factors or chemotactic molecules which also play an important role in 
wound repair (Song et al. 2002; Zhao et al. 1996a). 
 
 
 
 29 
 
Figure 2 
 
 
Figure 2: Model of corneal epithelial cells showing damaged epithelial cells produce electrical 
fields (EFs) which act as a guidance cue for cells to migrate toward the wound center (cathode). 
Transepithelial Potential (TEP). "Reprinted with permission from ADVANCES IN WOUND CARE 
3/2, (184-201) 2014, published by Mary Ann Liebert, Inc., New Rochelle, NY.” 
 
 Additionally, the role of CFTR in the process of cell migration has been 
studied and was shown to be an essential component of airway epithelial cell 
migration. Previous studies showed that CFTR was a major contributor in 
determining the rate of cell migration (Schiller, Maniak, O'Grady 2010; Sun et al. 
2011). This is due to multiple factors which include a role for CFTR in 
lamellipodia formation (Schiller, Maniak, O'Grady 2010), as well as the 
importance of CFTR in the generation of an EF following epithelial damage (Sun 
et al. 2011). Studies by Nguyen et al have shown that CFTR corrector VRT-325 
increased the rate of wound closure in cells that expressed the F508 mutation. 
This increase in wound closure was comparable to what was seen in wt-CFTR 
 30 
 
cells. It is thought that the increase of migration in the F508-CFTR cells after 
CFTR corrector is due to the up-regulation of CFTR in these cells (Trinh et al. 
2012). This is additional evidence that CFTR is essential in the process of wound 
repair in epithelial cells. Another important role of CFTR in the migration process 
is the effect it has on apical membrane expression of glycosphingolipid GM1. 
CFTR deficient cells have decreased levels of glycosphingolipid GM1 which 
plays an important role in 1-integrin activation, phosphorylation of FAK and p130 
Crk- associated substrate (CAS), all of which highly contribute to wound repair 
efficiency in airway epithelial cells (Itokazu et al. 2014). These results provide 
compelling evidence that CFTR and Cl- secretion is critical for the wound repair 
process. 
 
B. Scope of Thesis 
 Obstructive airway diseases like CF, asthma and COPD affects millions 
worldwide and significantly impairs the quality of life of the individuals who suffer 
from these airway diseases. Many people that have an obstructive airway 
disease take 2-agonists to help relieve symptoms such as of shortness of breath 
and wheezing. However studies have shown that the effects of 2-agonists on the 
airway epithelium could have significant negative side effects that could 
potentially lead to decreased symptom relief as well as increased airway 
infections (Bhagat, Swystun, Cockcroft 1996; Booth et al. 1996; Ramage et al. 
1994; Spina 2014). Although the effects of -AR stimulation on wound repair 
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have been well studied in keratinocytes and corneal epithelial cells, the effects of 
their activation on airway epithelial cell migration is poorly understood. The need 
for further investigation of the effects of 2-AR agonists on airway epithelial cell 
migration and overall lung health is important for understanding the underlying 
cellular and molecular mechanisms involved. A better understanding of these 
mechanisms may help to direct the course of drug development with improved 
effectiveness and minimal negative side effects.  
 Therefore, the overall hypothesis of this thesis is that chronic stimulation 
of 2-AR leads to down-regulation coupled to a reduction in CFTR expression 
and activity in the apical membrane that impairs mucociliary clearance and 
wound repair.  
The overall goal is to understand the mechanism of adrenergic regulation of 
CFTR function responsible for reductions in mucociliary clearance and airway 
wound healing. An understanding of this mechanism may aid in the development 
of new drugs to reduce the possible side effects of long-acting-agonists on 
wound healing associated with recurrent episodes of inflammation in patients 
with obstructive airway disease like asthma and CF.   
The first aim of this study is to investigate the effects -AR agonists have on 
mucociliary clearance and wound repair.  
Hypothesis: Stimulation of β2-AR with an agonist cause distinct downstream 
signaling pathways in airway epithelial cells. We propose that these agonists lead 
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to the activation of -arrestin signaling which produces inhibition of anion 
secretion and wound repair through a decrease in CFTR activity.  
The second aim of this study is to determine the effects -AR inverse ligand 
carvedilol has on mucociliary clearance and wound repair. 
Hypothesis:  Stimulation of 2-AR with carvedilol blocks G-protein signaling and 
activates -arrestin signaling, leading to a decrease in CFTR activity as well as a 
decrease in available CFTR in the apical membrane.  
The third and final aim of this study was to investigate the functional interactions 
between CFTR and 2-AR after -AR stimulation that accounts for the decrease 
in CFTR activity. 
Hypothesis:  Chronic β2-AR stimulation with an agonist inhibits CFTR activity 
through PP2a activation while β2-AR stimulation with inverse ligand carvedilol 
decreases CFTR activity through internalization and reduced surface expression 
of the β2-AR/CFTR signaling complex. These two mechanisms result in reduced 
CFTR channel activity that is responsible for the decrease in mucociliary 
clearance and wound repair.  
The results of these studies will provide an important understanding of the 
mechanisms responsible for the inhibitory effects β2-AR ligands have on 
mucociliary clearance and migration in airway epithelial cells. This will offer new 
knowledge of -AR effects on CFTR which could help reduce the possible 
negative side effects on mucociliary clearance and wound repair through new 2-
AR druge targets. 
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Chapter 2 
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
-Adrenergic Receptor Expression and Inverse Agonist Regulation of 
Anion Secretion in Human Airway Epithelial Cells 
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A. Summary 
 The objective of this study was to investigate the effects of air-liquid (ALI) 
and liquid-liquid (LLI) interface conditions on membrane localization of the 2-
ARs in human airway epithelial cells and to determine the actions of the inverse 
agonist carvedilol on anion secretion in this cell system. Calu-3 cells were grown 
to confluence on membrane filters under ALI or LLI conditions until monolayers 
reached a transepithelial resistance of ~1000 Ω∙cm2 and were then mounted in 
Ussing chambers. Under ALI conditions, basolateral stimulation with epinephrine 
(1 M) produced a large increase in CFTR-dependent short circuit current (Isc), 
consistent with stimulation of anion secretion that was significantly inhibited by 
the pan-specific -AR antagonist propranolol. In contrast when cells were grown 
under LLI conditions, basolateral stimulation with 1 M epinephrine produced a 
much smaller increase in Isc, indicating that culturing cells under ALI promotes 
the basoalteral expression of -ARs. Apical stimulation with the 2-AR agonist 
salbutamol (10M) caused an increase in anion secretion similar to what was 
observed with 10M 8cpt-cAMP. Initial treatment of Calu-3 cells with carvedilol 
caused a decrease in basal Isc and blocked the effect of 10M 8cpt-cAMP on 
Isc. Pretreatment with the microtubule disrupting agent nocodazole blocked the 
inhibitory effects of carvedilol on Isc. Furthermore, western blot analysis of Calu-
3 cells treated with carvedilol showed reduced expression of CFTR in the apical 
membrane, but no change in expression following stimulation with epinephrine. 
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These results suggest that carvedilol produces inhibition of cAMP-stimulated 
anion secretion by inducing endocytosis of CFTR from the apical membrane. 
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B. Introduction 
 Individuals with asthma, chronic obstructive pulmonary disease (COPD), 
and cystic fibrosis (CF) use -adrenergic receptor agonists to control and reduce 
symptoms of these respiratory diseases. These medications include short acting 
-agonists, albuterol and long acting -agonists, salmeterol (Patel et al. 2013; 
Ryall, Sillence, Lynch 2006). Each of these medications have selectivity for 2-
adrenergic receptors and are administered by inhalation. -agonists act on 
airway smooth muscle to promote bronchodialation and increased airflow into the 
lung. Furthermore they stimulate mucociliary clearance by increasing ciliary beat 
frequency and epithelial fluid secretion (Bennett 2002; Benovic 2002; Wanner, 
Salathe, O'Riordan 1996). Mucociliary clearance is a defense mechanism that 
consists of a layer of mucus that rests on the surface of a periciliary liquid (PCL) 
layer that bathes the apical membrane and cilia of the airway epithelium. Inhaled 
pathogens and other foreign materials become trapped within the mucus layer 
and are subsequently transported out of the airways by directional ciliary 
movement toward the mouth (Ganesan, Comstock, Sajjan 2013; Kilburn 1968)  
 The airway surface epithelium is important in regulation of the PCL layer 
through the coordinated actions of ion channels and transporters that participate 
in transepithelial Na+ absorption and anion secretion. The surface cells absorb 
sodium by a mechanism involving apical ENaC sodium channels and basolateral 
Na-K ATPase enzymes (Donaldson and Boucher 2007). Charge compensation 
and control of intracellular [K+] is achieved by parallel movement of K+ through K 
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channels present in the plasma membrane (Zhao et al. 2012). Inhibition of ENaC 
activity, either by addition of amiloride analogs or by reduced proteolytic 
activation of ENaC channels results in stimulation of anion secretion as a 
consequence of apical membrane hyperpolarization favoring anion efflux 
(Korbmacher et al. 2014; O'Grady, Jiang, Ingbar 2000). Secretion of chloride and 
bicarbonate induced by elevation of intracellular cAMP or [Ca2+]i involves 
activation of apical CFTR or calcium activated Cl channels (TMEM16A) 
expressed in series with Na-K-2Cl cotransport (NKCC1) proteins and Na-K 
ATPase enzymes located in the basolateral membrane (Hollenhorst, Richter, 
Fronius 2011). Additionally, basolateral anion uptake can be mediated by Cl-
HCO3 excahnge or by Na-(HCO3)x cotransport. Potassium recycling across the 
basolateral membrane can occur by cAMP-dependent activation of Kv7.1/MiRP2 
channels or KCa channel opening in response to increases in [Ca
2+]i depending 
upon the origin of the cells. (Grahammer et al. 2001; Wang et al. 2008). 
Regulation of  the depth of the PCL layer has been shown to be dependent on 
local autocrine signals including adenosine and nucleotide phosphates released 
from the airway epithelium and SPLUNC1, which controls proteolytic activation of 
ENaC in the apical membrane (Garcia-Caballero et al. 2009; Shan et al. 2011). 
Furthermore, changes in the thickness of the PCL layer are sensed and 
dynamically regulated by the surface epithelium in response to pathologic states 
such as microbial infection and allergic inflammation.   
 The production and secretion of mucus significantly contributes to 
mucociliary clearance. Submucosal glands are responsible for a large proportion 
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of mucus secretion in the upper airways (Ganesan, Comstock, Sajjan 2013). 
Delivery of mucus into the airway lumen is dependent on the coordinated 
regulation of serous and mucus cell secretions within the glands (Cho et al. 2012; 
Wine and Joo 2004) . Serous cells express high levels of CFTR in the apical 
membrane which facilitates anion secretion. Anion transport establishes an 
osmotic driving force for fluid secretion that increases the hydration of mucins 
secreted by mucus cells. (Wine and Joo 2004). Submucosal gland secretion is 
stimulated by cholinergic agonists that increase intracellular [Ca2+]i and by 2-
adrenergic receptor ligands that increase cAMP-dependent phosphorylation of 
CFTR (Bennett 2002; Benovic 2002; Verkman, Song, Thiagarajah 2003; Wanner, 
Salathe, O'Riordan 1996; Wine and Joo 2004). In patients with obstructive airway 
diseases such as asthma, COPD or CF, mucociliary clearance is significantly 
impaired due to lack of normal CFTR function, enhanced ENaC activity and over 
production of mucus resulting from chronic airway inflammation (Ganesan, 
Comstock, Sajjan 2013; Knowles and Boucher 2002; Mall et al. 1996; Stutts et al. 
1995; Wanner, Salathe, O'Riordan 1996). Reduced CFTR function and enhanced 
ENaC activity associated with the airway surface cells diminishes the depth of 
the PCL layer, resulting in compression of cilia by the mucus layer and restriction 
of ciliary movement. The increase in mucus production caused by activation of 
muscarinic receptor stimulation produces changes in PCL composition that can 
lead to formation of mucus plugs within smaller airways and increased risk of 
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infection (Knowles and Boucher 2002; Voynow and Rubin 2009; Wanner, 
Salathe, O'Riordan 1996).  
 In a recent study, epinephrine was reported to increase cAMP and 
intracellular Ca2+ in Calu-3 cells (an adenocarcinoma cell line expressing 
submucosal gland characteristics) grown under air-liquid interface conditions 
(Banga et al. 2014). This resulted in activation of CFTR and a Ca2+ activated 
chloride channels (CaCC) which resulted in an increase in transepithelial anion 
secretion. The initial transient increase in Isc was followed by a sustained current 
with diminishing oscillations over time. It was concluded that the CaCC 
responsible for the calcium-dependent component of the Isc was TMEM16A 
located in the apical membrane and together with CFTR these channels were 
responsible for the large increase in Isc produced by epinephrine and the 
associated oscillations. Moreover the results of this study indicated that 
TMEM16A and CFTR were functionally linked and coordinately regulated by 
increases in cAMP and [Ca2+]i .  
 The initial objective of the present study was to further examine the 
proposed interaction between TMEM16A and CFTR in Calu-3 cells using a 
CFTR deficient cell line. The second objective was to investigate the differential 
effects of the inverse 2-AR ligand carvedilol on basal anion secretion and 8-cpt 
cAMP-evoked anion secretion. The results indicated that CFTR silencing 
abolished the Isc response to basolaterally applied epinephrine and that the 
inhibitory effects of carvedilol on basal and 8-cpt cAMP-induced anion secretion 
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were related in part to a down-regulation of CFTR protein expression in the 
apical membrane.  
 
C. Materials and Methods 
Materials 
Eagles minimum essential medium with Earl’s salts (MEM), fetal bovine serum 
(FBS), nonessential amino acids, penicillin-strepomycin and Phosphate-Buffered 
Saline (PBS) were purchased from Life Technologies (Carlsbad,CA). Trypsin 
was ordered from Lonza (Allendale NJ). Western blot protein markers, Magic 
Mark, See Blue, nitrocellulose membranes, 10% Bis-Tris gels and Enhanced 
Chemiluminescence (ECL) reagent were purchased from Life Technologies 
(Carlsbad, CA). Restore Western Blot Stripping Buffer and Cell Surface Protein 
Isolation kits were purchased from Thermo Scientific (Rockford, IL). Bovine 
Serum Albumin (BSA), carvedilol, epinephrine, 8cpt-cAMP, salbutamol and 
nocodazole were acquired from Sigma Aldrich (St Louis, MO). The selective 2 
receptor antagonist ICI-118,551 was obtained from Tocris Bioscience, (Bristol, 
UK). CFTR antibody (#2269) used for western blots was purchased from Cell 
Signaling (Danvers MA). -tubulin primary antibodies and secondary goat anti-
rabbit and goat anti-mouse antibodies were purchased from Santa Cruz 
Biotechnology (Dallas, TX). Anti -Tubulin for westerns was ordered from 
Millipore. Antibodies used for IHC, 2-Adrenergic receptor antibody (Ab13989), 
anti-CFTR (Ab2784) antibody and secondary goat anti-chicken IgY Alexafluor 
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(Ab150169) antibodies were purchased from Abcam (Cambridge, MA). DAPI and 
slow fade reagent were purchased from Life Technologies (Carlsbad, CA). 
 
Cell Culture 
 Human airway adenocarcinoma (Calu-3) cells were maintained in MEM 
medium containing 10% FBS, 1% nonessential amino acids and 1% penicillin-
strepomycin in a humidified 5% CO2 incubator at 37°C. 
Apical membrane biotinylation 
 Calu-3 cells were grown on T75 flasks until 90% confluent. Cells were 
treated and membrane proteins isolated using a cell surface protein isolation kit 
from Thermo Scientific (Rockford, IL). Briefly, the procedure involved treating 
cells with 10M epinephrine or carvedilol for 30 minutes. Cells were then washed 
in ice cold PBS and surface proteins labeled with biotinylation reagent (Sulfo-
NHS-SS-Biotin). Labeled protein was subsequently harvested and affinity purified 
using NeutrAvidin Agarose Resin. Proteins were eluted using 50mM DTT in RIPA 
buffer and placed on a heat block for 5 minutes at 95°C, then spun at 1000 x g 
for 2 minutes. Isolated cell surface protein was then analyzed by western blot.  
Western Blot analysis 
 Biotinylated membrane proteins were loaded onto a 10% bis-tris gel with a 
protein marker lane containing See Blue and Magic Mark. The gel was 
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transferred onto a nitrocellulose membrane and blocked in 5% milk/Tris-Buffered 
Saline with 0.2% Tween 20 (TBST) for 20 hours at 4°C. Membranes were then 
incubated overnight at 4°C with CFTR antibody (#2269) at a 1:1000 dilution and 
washed with TBST 3 times (5 minutes each wash), then incubated at room 
temperature for 1 hour with goat anti-rabbit IgG-HRP (1:7500 dilution). 
Membranes were then washed 3 times (5 minutes each wash) before incubation 
in ECL reagent for 1 min. After X-ray film exposure, blots were stripped for 5 
minutes in Restore Stripping reagentand re-blocked in 5% milk/TBST overnight 
at 4°C. Membranes were then incubated in -tubulin antibody (1:500 dilution) 
overnight at 4°C and washed 3 times in TBST before incubation with secondary 
goat anti-rabbit IgG-HRP antibody for 1 hour at room temperature. Afterwards, 
blots were placed in ECL reagent for 1 minute and exposed to X-ray film. 
Immunohistochemistry 
 Cells were grown on Snapwell filters until confluent monolayers were 
formed. Monolayers were then fixed with 4% paraformaldehyde for 30 minutes 
followed by a 20 minute incubation with 0.1% TritonX100. Monolayers were 
washed 3 times between steps and blocked in 3% bovine serum albumin (BSA) 
for 2 hours, then incubated with primary 2-AR antibody (Ab13989) and primary 
anti-CFTR antibody (Ab2784) overnight in 3% BSA. Monolayers were 
subsequently incubated in secondary Alexafluor antibodies diluted in PBS for 45 
minutes and  the filters washed 5 times with PBS. DAPI diluted in PBS was 
applied to  the monolayers for a period of 10 minutes then removed by washing 5 
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times with PBS. Filters were then mounted on slides and membrane localization 
of 2-AR and CFTR was determined by confocal microscopy (60X oil immersion). 
Electrophysiology 
 Transepithelial resistances were measured using a EVOM epithelial 
voltohmeter attached to Ag/AgCl 'chopstick' electrodes [World Precision 
Instruments (WPI), New Haven, CT]. CFTR activity was measured using 
monolayers (~1000 Ω∙cm2) that were mounted in Ussing chambers and bathed 
on both sides with standard saline solution  containing (in mM) 130 NaCl, 6 KCl, 
1.5 CaCl2, 1 MgCl2, 20 NaHCO3, 0.3 Na H2PO4, and 1.3 Na2HPO4, pH 7.4, which 
was maintained at 37°C and bubbled with 95% O2-5% CO2. CFTR was activated 
using 10M 8cpt-cAMP and the short circuit current (Isc) was acquired using 
Axoscope8.0 software (Molecular Devices, Sunnvale CA)). 
 For experiments involving measurement of the apical membrane CFTR 
current, amphotericin B (15 μM) was used to perforate the basolateral membrane 
of the monolayers mounted in Ussing chambers. The basolateral (intracellular) 
surface was bathed with intracellular solution (in mM) 130 K-methanesulfonate, 5 
KCl, 8 NaCl, 20 KHCO3, 30 mannitol, 1 MgSO4, 1 CaCl2, and 10 glucose (pH 
7.4), while the apical membrane (extracellular) was bathed with physiological 
saling solution (in mM) 70 Na-methanesulfonate, 5 KCl, 68 NaCl, 20 NaHCO3, 1 
MgSO4, 1 CaCl2, and 10 glucose (pH 7.4). CFTR was activated using 5 M 8cpt-
cAMP then subsequently treated with 10M carvedilol, then 20 M CFTRinh-172 
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and the apical membrane currents acquired using pCLAMP 8.2 (Molecular 
Devices). 
Statistical Analysis 
 Statistical significance was determined using an unpaired, two-tailed t-test 
(for single comparisons) or an ANOVA followed by a Bonferroni post test (for 
multiple comparisons). Results are expressed as the mean +/- standard error. A 
value of p< 0.05 was considered significant. 
D. Results 
 Basolateral treatment of Calu-3 cells with 1M epinephrine increased Isc 
in monolayers that were grown under ALI and LLI conditions (Figure 1). For both 
growth conditions the Isc increase was nearly abolished following treatment with 
the CFTR inhibitor, CFTRinh-172. Additionally, the response toepinephrine was 
significantly greater for the ALI condition compared to the LLI condition. 
Pretreatment of cells with 10M propranolol on the basolateral membrane 
effectively blocked the epinephrine response seen in control cells. Furthermore, 
epinephrine had no effect on Isc in shCFTR cells, indicating that the increase in 
Isc produced by -AR activation was dependent on CFTR expression in the 
apical membrane. 
 Localization of CFTR and 2-AR were observed by immunohistochemistry 
using confocal microscopy. Calu-3 cells were grown on filters until confluent and 
fixed with 4% paraformaldehyde before exposure to CFTR and 2-AR antibodies. 
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Fixed cells showed expression of both CFTR (in green) and the 2-AR (in red). 
Moreover, the yellow punctate labeling pattern indicates that the two proteins 
exhibit co-localization within the apical membrane of Calu-3 cells (Figure 2A). 
Figure 2B shows the effects of 2-AR stimulation with salbutamol, a selective 2-
AR agonist and the effects of the cell permeable cyclic AMP analog, 8-cpt cAMP 
on Isc. The increase in current produced by apical salbutamol and 8cpt-cAMP 
reflects stimulation of transepithelial anion secretion. Addition of CFTRinh-172 
caused nearly complete inhibition of salbutamol evoked anion secretion. 
Furthermore apical addition of 10M salbutamol to Calu-3 cells where CFTR 
expression was silenced by constitutive expression of shRNA (shCFTR cells) 
showed no increasae in anion secretion. These results demonstrate that CFTR is 
involved in producing the increase in Isc following stimulation with 2-AR 
agonists. Similarly, monolayers treated with 10M 8cpt-cAMP showed an 
increase in Isc that was absent in shCFTR cells. Figure 2C shows the time 
course of the 8cpt-cAMP effect on Isc. At the peak of the response, monolayers 
were apically treated with 10M carvedilol, an inverse ligand that was previously 
shown to interact with the 2-AR (Kveiborg et al. 2007; Vanderhoff, Ruppel, 
Amsterdam 1998). Unlike salbutamol, carvedilol produces a sustained decrese in 
Isc. However pretreating monolayers with 10M ICI-118,551 (a selective 2-AR 
antagonist) blocks the effects of carvedilol on 8cpt-cAMP evoked anion secretion 
(Figure 2D). Inhibition of the carvedilol response by ICI-115,551 demonstrates 
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that the effect of carvedilol is mediated by the 2-AR. A summary of results from 
these experiments is presentedin figure 2E.   
 Data presented in figure 3 shows the effect of 10M carvedilol on the 
basal Isc of Calu-3 cell monolayers. When the monolayers were subsequently 
treated with 10M 8cpt-cAMP no significant effect on Isc was observed (Figure 
3A). In contrast, monolayers pretreated with 10M ICI-118,551 did not exhibit a 
decrease in basal Isc following apical addition of 10M carvedilol. Furthermore, 
ICI-118,551 rescued the effect of 8cpt-cAMP on anion secretion (Figure 3B). 
These experiments demonstrate that treatment with carvedilol inhibits basal 
anion secretion and it is dependent on activation of the 2-AR. A summary of 
these results is presented in Figure 3C. 
 To determine whether the effect of carvedilol on Isc was the result of 
CFTR inhibition, apical membrane Cl- currents were measured in Calu-3 
monolayers where the basolateral membrane resistance was eliminated following 
treatment with amphotericin B. For these experiments the basolateral surface of 
the monolayer was bathed in intracellular solution and the apical membrane was 
bathed in physiological saline solution. The apical membrane was held at zero 
mV and stepped from -30 to +30 mV in 5 mV increments to measure the CFTR 
conductance. CFTR was stimulated by treating the cells with 8cpt-cAMP, which 
evoked a significant increase in the slope of the CFTRinh-172 sensitive current-
voltage (I-V) relationship. Addition of 10M carvedilol inhibited the 8cpt-cAMP 
evoked Cl- current and significantly reduced the CFTR conductance (Figure 4A). 
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In contrast, no significant increase in apical Cl- current or conductance was 
observed in shCFTR cells (Figure 4B). These results indicate that the inhibitory 
effect of carvedilol on 8cpt-cAMP stimulated anion secretion in Calu-3 cells is the 
result of a decrease in CFTR activity. To determine if the decrease in CFTR 
conductance was associated with a reduction in apical CFTR expression, Calu-3 
cells were exposed to 30M nocodazole for 2 hours to disrupt microtubule-
dependent retrieval of proteins from the plasma membrane. Cells treated with 
nocodazole showed microtubule disruption as indicated by a decrease in tubulin-
containing filaments (Figure 5A). Furthermore, western blot analysis revealed 
that cells treated with nocodazole for 30 minutes, 1 hour and 2 hours exhibited a 
decrease in monomeric -tubulin associated with the NP-40 insoluble fraction, 
indicating an increase in microtubule depolymerization (Vossenkamper et al. 
2007) (Figure 5B). The effect on CFTR conductance was then determined using 
monolayers pretreated with 30M nocodazole prior to stimulation with 10M 
8cpt-cAMP and subsequent treatment with carvedilol. Cyclic AMP caused an 
increase in CFTR conductance in both control and treated cells, however 
addition of 10M carvedilol failed to reduce CFTR conductance as observed in 
control monolayers (Figure 5C). These results suggest that a portion of the 
inhibitory effect of carvedilol on anion secretion is dependent on an intact 
microtubule network.  
 The effect of microtubule disruption on carvedilol mediated inhibition of 
anion secretion is shown in Figure 6. Monolayers were initially treated with 30M 
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nocodazole for 2 hours prior to stimulation with 10M 8cpt-cAMP. Nocodazole 
treated monolayers exhibited an increase in Isc that was similar to control 
conditions. However the effect of carvedilol after addition of 8cpt-cAMP was 
blocked in nocodazole treated cells (figure 6C). These results are consistent with 
the data reported in figure 5 demonstrating that carvedilol inhibition of Isc was 
dependent on a functional microtubule network.  
 Data presented in figure 7 shows the level of CFTR protein expression 
within the apical membrane of Calu-3 cells using surface biotinylation. For these 
experiments cells were treated with 10M carvedilol or epinephrine prior to 
biotinylation. Carvedilol treatment showed a significant decrease in CFTR protein 
expression in the apical membrane compared to the control cells. In contrast, 
epinephrine showed no significant decrease in apical expression compared to 
the controls (Figure 7C). These results suggest that at least a portion of the 
inhibitory actions of carvedilol on 8ctp-cAMP stimulated anion secretion results 
from a decrease in CFTR protein levels at the plasma membrane.  
 
E. Discussion 
 An interesting and previously unreported finding from the present study 
was the observation that the response to -AR agonist stimulation on the 
basolateral membrane depends on growth conditions. Cells grown under ALI 
produced a significantly greater response to basolateral stimulation with 
epinephrine compared to cells under LLI conditions. One possible explanation for 
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this effect is that the expression of -AR protein in the basolateral membrane is 
enhanced under ALI resulting in a larger Isc response when stimulated with -AR 
agonist. Another possibility is that coupling between the -AR and adenylyl 
cyclase is enhanced, resulting in a greater level of cAMP production relative to 
the LLI condition. It is also possible that the larger Isc response is not directly 
related to -AR expression or signaling, but is the result of a change in the level 
of Kv7.1/MiRP2 expression in the basolateral membrane, which could lead to a 
larger increase in basolateal K+ efflux and a greater driving force for Cl- exit 
acrosss the apical membrane. Additional experiments will be necessary in order 
to determine whether one or more of these possibilities is responsible for the 
effects of ALI on anion secretion.  
 2-AR are G-Protein coupled receptors (GPCR) that when stimulated with 
an agonist such as salbutamol, activation of Gs signaling occurs. This leads to 
downstream activation of adenylyl cyclase and cAMP (Benovic 2002) When an 
agonist binds to a receptor causing activation of the receptor (Leurs, Church, 
Taglialatela 2002). Inverse agonists bind to the inactive state of a receptor and 
promote an opposite response of an agonist, eliminating basal activity of the 
receptor (DG Lambert 2004; Leurs, Church, Taglialatela 2002; Maack et al. 2000; 
Maack et al. 2001; Parra and Bond 2007). Biased ligands bind to a receptor and 
elicit a selective signal while eliminating and or preventing other signals produced 
by the receptor (Steen et al. 2014; Tao and Conn 2014). Carvedilol is an inverse 
agonist commonly used in cardiovascular medicine for heart failure and 
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hypertension whose effect include increase of left ventricular function, and 
reductions of blood pressure (Vanderhoff, Ruppel, Amsterdam 1998). It does so 
by binding to -adrenergic receptors leading to vasodilatation and decreasing 
heart rate (Kveiborg et al. 2007). Little is known about the effects of carvedilol on 
airway epithelial cells. These studies show that treating cells with carvedilol after 
stimulation with 8cpt-cAMP, a known activator of CFTR dependent anion 
secretion in airway epithelial cells (Schultz et al. 1999) causes a significant 
decrease in activated anion secretion as well as basal current decrease 
carvedilol pretreatment. Measurements of the apical membrane anion 
conductance following stimulation with 8cpt-cAMP revealed that the carvedilol-
induced decrease in Isc resulted from the inhibition of CFTR. These results are 
consistent with carvedilol acting as an inverse agonist. The ability of ICI-118-551 
to block the carvedilol effect on anion secretion and to rescue the 8cpt-cAMP 
response suggests that the effect of carvedilol is mediated through the 2-AR and 
does not act as a CFTR blocker.  
 To determine if carvedilol-induced inhibition of CFTR activity was due to 
internalization of the channel, nocodazole was used to depolymerize 
microtubules and decrease vesicle transport (Vasquez et al. 1997; 
Vossenkamper et al. 2007). Treatment of Calu-3 cells for 30 minutes with 
nocodazole produced a significant reduction in alpha-tubulin polymerization and 
rescued CFTR channel activity and 8cpt-cAMP dependent anion secretion in 
carvedilol treated cells. These results provide indirect evidence suggesting that 
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the effect of carvedilol is due to removal of CFTR channels from the apical 
membrane. Furthermore, subsequent apical surface biotinylation experiments 
revealed that carvedilol stimulation resulted in a significant decrease in CFTR 
protein expression compared to untreated controls and epinephrine treated cells. 
These results indicate that carvedilol inhibits CFTR channel function by 
stimulating internalization of the channel.  
 It has been shown in previous studies that 2-AR and CFTR co-localize in 
airway epithelia forming a signaling complex at the apical membrane (Naren et 
al. 2003; Taouil et al. 2003). This signaling complex includes NHERF and EBP50 
which physically couple 2-AR and CFTR through interactions with their 
respective PDZ domains. These scaffolding proteins help to stabilize CFTR at 
the apical membrane (Taouil et al. 2003). When an agonist such as epinephrine 
binds to the 2-AR receptor two distinct signaling pathways are activated. 
Release of Gs  subunit from the 2-AR ultimately increases CFTR channel 
activity by increasing production of cAMP and stimulation of PKA-mediated 
phosphorylation of the channel. (Naren et al. 2003; Taouil et al. 2003) . Activation 
of PKA and phosphorylation of CFTR is thought to be responsible for the 
disassociation of the CFTR and 2-AR complex (Naren et al. 2003). The second 
pathway activated by binding of epinephrine involves -arrestin-dependent 
signaling. After a period of time following agonist binding to the receptor G-
Protein receptor kinases (GRKs) are recruited to the plasma membrane where 
they phosphorylate the C-terminal tail of the 2-AR (Benovic 2002; Han et al. 
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2012; Reiter et al. 2012). Conformational changes associated with this 
phosphorylation facilitate binding of -arrestin, a cytosolic adaptor protein, to the 
receptor (Shenoy et al. 2009; Shenoy and Lefkowitz 2011). This allows for 
recruitment of Nedd4 an E3 ligase that ubiquinates the receptor effectively 
labeling the protein for internalization and targeting the receptor to lysosomes 
(Shenoy et al. 2007; Shenoy 2007; Shenoy et al. 2008; Shenoy and Lefkowitz 
2011). However when carvedilol binds to the 2-AR, a distinct conformational 
change occurs that blocks Gs signaling, but allows for GRK recruitment (Kim et 
al. 2008; Kim et al. 2005; Shenoy and Lefkowitz 2011; Wisler et al. 2007). The 
resulting -arrestin binding recruits MARCH2, a different E3 ligase that 
ubiquinates the C-terminal tail of the receptor (Han et al. 2012). This leads to 
protein internalization and degradation through a process of endocytosis and 
lysosomal degradation (Han et al. 2012; Shenoy and Lefkowitz 2011; Wisler et 
al. 2007). Unlike epinephrine where the 2-AR-CFTR signaling complex 
disassociates after epinephrine binding leading to 2-AR internalization and 
leaving CFTR in the apical membrane, carvedilol stimulation may not allow for 
the 2-AR-CFTR complex to disassociate. This is due to the inhibition of Gs 
signaling (Han et al. 2012; Naren et al. 2003). Presumably, this would result in 
internalization of the entire signaling complex.  
 There have been many studies on the therapeutic potential of bias ligands 
in a variety of diseases including cardiovascular, metabolic, osteoporosis, HIV 
and cancer. For example carvedilol is used in treatment of cardiovascular 
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disease because it provides cardioprotection by promoting increased expression 
of epidermal growth factor receptor (EGFR) and preventing the activation of G-
Protein signaling, which when chronically stimulated may have detrimental 
cardiac effects (Drake et al. 2008; Wisler et al. 2007). The angiotension II type 1 
receptor (AT1R) is another receptor that -arrestin bias ligand stimulation may 
provide beneficial effects to patients with heart failure by increasing cardiac 
function (Whalen, Rajagopal, Lefkowitz 2011a; Whalen, Rajagopal, Lefkowitz 
2011b). The effects of -arrestin bias ligands on patients with osteoporosis has 
been shown to have great potential by increasing production of anabolic bone 
formation without activating bone resorption. G-Protein bias ligands also have 
great potential for treating diseases such as congenital nephrogenic diabetes 
insipidus (cNDI) a disease that has a mutated vasopressin receptor (V2R). In 
cND1 G-Protein inverse ligands act as a pharmacologic chaperones aiding in the 
restoration of the V2R misfolded protein, rescuing receptor function and 
promoting G-Protein signaling while preventing -arrestin signaling (Whalen, 
Rajagopal, Lefkowitz 2011a). The prevention of -arrestin signaling prevents the 
internalization of the receptor allowing the receptor to be available in the 
membrane for continuous stimulation. 
 It has also been suggested that inverse agonists may play an important 
therapeutic role in diseases that involve constitutively active GPCR because of 
their effects on decreasing the basal activity of the receptor (Tao and Conn 
2014). Previous studies have shown the potential therapeutic use of -inverse 
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agonists on asthma in the murine model by decreasing inflammatory cells and 
cytokines (Matera, Calzetta, Cazzola 2013; Nguyen et al. 2008). Inverse agonists 
have also been thought to have therapeutic benefits in metabolic disease such 
as obesity (Cameron, Bhattacharya, Loomis 2014; Tao and Conn 2014) playing a 
role as pharmacologic chaperones, correcting misfolded proteins (Tao and Conn 
2014) and  acting as GPCR blockers, limiting the constitutive activity of the 
receptors (Cameron, Bhattacharya, Loomis 2014). Studies on the use of bias 
ligands and inverse agonists as therapeutic agents will continue to be done 
focusing on the reduction of potential detrimental side effects and promoting 
symptom relief as well as potential disease reversal. 
 It is evident through these studies that targeting receptors with inverse 
agonists not only help in the understanding of downstream signaling 
mechanism(s) of the 2-AR-CFTR signaling complex but also could potentially 
serve as a tool to develop new drugs for chronic -agonist users. These new 
drugs could work in the opposite way of carvedilol, targeting the Gs signaling 
pathway and promoting CFTR activity while limiting the negative effects of GRK 
signaling.  
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Figure 1 
  
Figure 1: Epinephrine stimulated anion secretion on basolateral membrane of Calu-3 cells where 
propranolol blocked anion secretion. A: Isc tracing showing the effects of epinephrine and 
propranolol (10M) on the evoked anion secretion of basolateral membranes of Calu-3 cells 
grown in air liquid interface (ALI). B: Summary bar graph showing the effects of epinephrine 
(1M) and epinephrine + CFTRinh172 (20 M) on basolateral membrane Isc of wild type Calu-3 
cells in ALI, wild type Calu-3 cells in liquid liquid interface (LLI), propranolol treated (P) Calu-3 
cells, or CFTR deficient (shCFTR) Calu-3 cells. 
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Figure 2 
 
Figure 2: Immunohistochemistry and effects of 2-AR ligands on 8cpt-cAMP (10M) stimulated 
anion secretion. A: Confocal images showing membrane localization of CFTR (green), 2-AR 
(red) and the superimposed image of both antibody-labeled proteins expressed in Calu-3 cells. 
The yellow color indicates co-localization of the CFTR and 2-AR in the superimposed image. B: 
Summary bar graph showing the effects of salbutamol (10M) and 8cpt-cAMP (10M) on Isc of 
wild type Calu-3 cells or CFTR deficient (shCFTR) Calu-3 cells. Resulst show the change in Isc 
(= hatched bar) after salbutamol or 8cpt-cAMP treatment from basal Isc. C: Isc tracing showing 
the effects of carvedilol on 8-cpt cAMP evoked anion secretion. D: Isc tracing showing that the 2-
AR-selective antagonist ICI-118,551 (10M) blocks the inhibitory effect of carvedilol on 8cpt-
cAMP evoked anion secretion. E: A summary of Isc results comparing control monolayers to 
monolayers pretreated with ICI-118551 and monlayers treated on the basolateral membrane 
(BLM).   
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Figure 3 
 
Figure 3: Carvedilol inhibits basal and 8cptcAMP stimulated anion secretion whereas the 2-AR 
antagonist ICI-118,551 rescues 8cpt-cAMP evoked anion secretion. A:Carvedilol (10M) 
decreases the basal current and blocks the effects of 8cpt-cAMP on anion secretion. B: 
Monolayers pretreated with 10M ICI-118551 blocks the effect of carvedilol on basal anion 
secretion and rescues the effect of 8cpt-cAMP on Isc. C: Summary graph showing the effects of 
salbutamol, 8cpt-cAMP and carvedilol on Isc.  
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Figure 4 
 
 
Figure 4: Measurement of CFTRinh-172 sensitive apical membrane currents using amphotericin B 
permeablized Calu-3 monolayers. A: Basal, 8cpt-cAMP (10M) stimulated and 8ctp-cAMP 
stimulated, carvedilol inhibited CFTR currents evoked by a voltage step protocol where 
monolayers were held at zero mV and stepped from -30 to +30 mV in 5 mV increments. B: Apical 
membrane conductance measurements obtained from the slopes of I-V relationships of 
experiments shown in part A. (apical current traces of wild type Calu-3 cells and shCFTR cells at 
rest (grey), after addition of 8cpt-cAMP (red) and following addition of carvedilol to the apical 
solution after stimulation with 8cpt-cAMP (blue hatched).  
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Figure 5 
 
Figure 5: Effects of microtubule disruption with nocodazole on carvedilol-dependent inhibition of 
8cpt-cAMP stimulated anion secretion. A: Images of Calu-3 cells 2 hours after incubation with 30 
M nocodazole; Note the loss of filament structure compared to untreated control cells. B: 
Western blot analysis of -tubulin protein expression in Calu-3 cells treated with Nocodazole at 0 
minutes (C,), 30 minutes (lane 3), 1 hour (lane 2) and 2 hours (lane 1) C: Bar graph displaying 
the effect of carvedilol mediated inhibition of CFTR conductance in control and nocodazole 
treated cells.  
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Figure 6 
 
Figure 6: The effects of nocodazole on carvedilol-dependent regulation of 8cpt-cAMP evoked 
anion secretion. A: 8cpt-cAMP dependent anion secretion is inhibited by addition of 10M 
carvedilol. B: Pretreatment of monolayers with 30M nocodazole for 2 hours blocks the inhibitory 
effects of carvedilol on 8cpt-cAMP stimulated anion secretion. C: Summary graph showing that 
the effect of carvedilol on the 8cpt-cAMP stimulated increase in Isc was dependent on a 
functional microtubule network.  
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Figure 7 
Figure 7: Western blot analysis showing the effects of carvedilol and epinephrine on expression 
of CFTR in the plasma membrane. A: Western blot showing CFTR and -tubulin (loading control) 
protein present in biotinylated membranes from Calu-3 cells treated with carvedilol or epinephrine 
relative to untreated control cells. B: Analysis of the relative intensity of CFTR bands from four 
separate biotinylation experiments revealing a decrease in the level of CFTR protein following 
treatment with 10M carvedilol for 30 minutes. 
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Chapter 3 
 
2-Adrenergic Receptor Stimulation Inhibits Cell Migration and 
Epithelial Restitution by a Mechanism Involving CFTR 
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A. Summary 
 The objective of this study was to investigate the effects of -adrenergic 
receptor stimulation on airway epithelial cell migration and its effects on CFTR 
activity in airway epithelial cells. These studies were performed using normal 
human bronchial epithelial (NHBE) cells and Calu-3 cells which were grown to 
confluence on impedance sensing chamber arrays, each containing a circular 
250 m diameter electrode. Wound repair was monitored by continuously 
applying alternating current (~1 μA, 15 kHz) and measuring increases in 
impedance as cells migrated onto the electrode surface. Exposure to 10M 
epinephrine produced a significant delay in wound closure while pretreatment 
with the pan-specific -adrenergic receptor antagonist propranolol (10M) 
abolished the inhibitory effects of epinephrine. These results were also confirmed 
in human vaginal epithelial cells (hVE) and human cervical epithelial cells (hCE). 
The inhibitory effect on migration was also observed after stimulation with the 
selective 2-AR agonist salbutamol (10M) however no effect was observed 
when cells were treated with 10M dobutamine a 1-AR specific agonist. These 
results indicated that the effect on migration resulted from activation of the 2-AR. 
Moreover, inhibition of CFTR activity by addition of 20M CFTRinh-172 or using 
CFTR knockout cells blocked any further decrease in migration rate after addition 
of 10M epinephrine, signifying that the effects on cell migration were dependent 
on CFTR activity. Carvedilol, an inverse ligand, was also shown to cause a 
decrease in cell migration and wound repair similar to the effects of epinephrine. 
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Furthermore a reduction in lamellipodia area was observed after epinephrine 
treatment that was similar to the effect of CFTRinh-172. These results 
demonstrated that airway epithelial migration and wound repair is significantly 
reduced following exposure to -adrenergic receptor agonists and that this effect 
involves inhibition of CFTR channel activity. 
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B. Introduction 
The conducting airways are composed of several cell types, including basal, 
secretory, ciliated and neuroendrocrine cells (Hackett et al. 2011; Hajj et al. 
2007a; Roomans 2010; Yang and Chen 2014), which play an important role in 
maintaining a functional airway epithelium. When the epithelium is injured, 
regeneration and repair take place. Basal cells are progenitor cells within the 
airways that can differentiate into ciliated or secretory cells, (Crystal et al. 2008; 
Hajj et al. 2007a; Rock et al. 2009; Roomans 2010; Voynow et al. 2005; Yang 
and Chen 2014). There is also evidence that Clara cells can differentiate into 
ciliated cells following injury.(Hajj et al. 2007a; Hong et al. 2001; Stripp and 
Reynolds 2008; Teisanu et al. 2011; Voynow et al. 2005; Yang and Chen 2014) 
The process of wound repair typically involves the migration of progenitor cells 
into the damaged region of the epithelium. Cells at the edge of the wound form 
lamellipodia, pseudopod-like structures that facilitate ameoboid movement that 
allow the cells to migrate towards the center of the wound (Coraux et al. 2008; 
Lu, Reinach, Kao 2001). The migration is directed in part, by an electric field (EF) 
that spontaneously occurs with development of the wound (Chiang, Robinson, 
Vanable 1992; Soong et al. 1990; Sun et al. 2011; Zhao et al. 1996a). This EF 
has been shown to direct migrating cells by a process commonly referred to as 
electrotaxis (Song et al. 2002; Zhao et al. 1996a; Zhao et al. 1996b). A previous 
study by Schiller et al. (2010) showed that CFTR was essential in the migration 
of airway epithelial cells and Sun et al. (2011) showed that the channel was 
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responsible for the EF generated after wounding. Patients that suffer from Cystic 
Fibrosis (CF) lack functional CFTR in the apical membrane of airway epithelial 
cells and there is evidence indicating that these individuals are unable to 
effectively and efficiently repair damaged epithelium after injury, contributing to 
chronic infection and inflammation (Boucher 2004; Chmiel and Davis 2003; 
Guggino and Stanton 2006; O'Sullivan and Freedman 2009; Wanner, Salathe, 
O'Riordan 1996). 
 Most individuals that suffer from CF, asthma or COPD take -adrenergic 
receptor (AR) agonists to dilate their airways to increase airflow into the lungs 
and to increase ciliary beat frequency aiding in mucociliary clearance  (Cazzola 
and Matera 2014; Salathe 2002; Ulrik 2014). However it has been shown that 2-
AR agonists can lead to a loss in bronchioprotection, resulting in an increased 
risk of infection (Bhagat, Swystun, Cockcroft 1996; Booth et al. 1996; Ramage et 
al. 1994; Spina 2014). Long acting 2-AR agonists such as salmetrolol have been 
shown to cause down-regulation of the 2-AR (Walker et al. 2011; Wasilewski, 
Lougheed, Fisher 2014). This leads to a decrease in availability of the receptor to 
promote bronchiodilatation preventing fast acting, therapeutic effects of the 
agonist (Spina 2014; Walker et al. 2011; Wasilewski, Lougheed, Fisher 2014). 
Furthermore, -agonists have been shown to decrease the rate of cell migration 
in other epithelial cell types including keratinocytes and corneal epithelial cells 
(Chen, Hoffman, Isseroff 2002; Pullar et al. 2006; Pullar et al. 2007). However 
less is known about their effects in airway epithelia.   
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 The objective of the present study was to investigate the effects -
agonists have on airway epithelial cell migration during the process of wound 
closure using Calu-3 cells, a model airway epithelial cell line of submucosal gland 
origin and in normal human bronchial epithelial (NHBE) cells. The effects of -
agonists on vaginal and cervical epithelial cell migration were also investigated. 
Additionally, the effect of the inverse agonist carvedilol on migration was also 
determined using airway epithelial cells. The results demonstrated that -
agonists produced a significant inhibition of cell migration in each of these cell 
systems during wound repair, similar to what was previously observed in 
keratinocytes and corneal epithelial cells. Inhibition of CFTR blocked the effect of 
-agonists on airway epithelial cell migration, indicating that loss of CFTR 
function was associated with the decrease in migration rate. Additionally, -
agonists caused diminished protrusion of lamellipodia similar to the actions of the 
CFTR inhibitor CFTRinh-172. Our results of this study provide evidence that 
stimulating the 2-AR with an agonist or inverse ligand leads to a decrease in 
CFTR function using two different mechanisms, both of which cause a significant 
decrease in the cell migration rates of these cells.  
C. Materials and Methods 
Materials 
Eagles minimum essential medium with Earl’s salts (MEM), fetal bovine 
serum (FBS), nonessential amino acids, penicillin-strepomycin and Phosphate-
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Buffered Saline (PBS) were purchased from Life Technologies (Carlsbad,CA). 
Bronchial epithelial cell media BEGM with bullet kits and Trypsin were ordered 
from Lonza (Allendale NJ). Bovine Serum Albumin (BSA), CFTRinh- 172, 
carvedilol, epinephrine, 8cpt-cAMP, salbutamol, L-Cysteine were acquired from 
Sigma Aldrich (St Louis, MO). The selective 2 receptor antagonist ICI-118,551 
was obtained from Tocris Bioscience, (Bristol, UK). Bovine Collagen Type 1 was 
purchased from BD biosciences (San Jose, CA).Texas Red X phalloidin, 
SlowFade Gold antifade and Superscript II reverse transcriptase were purchased 
from Invitrogen. RNeasy Mini Kit was purchased from Qiagen. Turbo DNase was 
purchased from Ambion (Applied Biosystems Foster City, CA), SYBR green 
Brilliant III master mix and passive reference dye for qualitative real-time PCR 
(qRT-PCR) were purchased from Agilent Technologies (Santa Clara, CA). ECIS 
arrays were purchased from Applied Biophysics (Troy, NY).  
Cell Culture 
 Normal Human Bronchial Epithelial (NHBE) cells were maintained in 
complete bronchial epithelial cell growth media (BEGM) with provided bullet kits 
which are SingleQuots of bovine pituitary extract, epinephrine, 
gentamicin/amphotericin-B, human epidermal growth factor, hydrocortisone, 
insulin, retinoic acid, transferrin, and triiodothyronine. The human airway 
adenocarcinoma cell line Calu-3 WT, shCFTR and shALTR cells were 
maintained in MEM medium containing 10% FBS, 1% nonessential amino acids 
and 1% penicillin-strepomycin. The human vaginal epithelial cells (hVE) and the 
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ectocervical cells hCE were obtained from ATCC (Manassas, VA) and were 
maintained in Keratinocyte-SFM (1X) from life technologies (Carlsbad,CA), 
containing 10% FBS and 0.1% penicillin-strepomycin. All cells were maintained 
in a humidified 5% CO2 incubator at 37°C. 
Quantitative RT-PCR 
Expression of -AR was determined by qRT-PCR. Total RNA was 
extracted from monolayers using RNeasy Mini Kit from Qiagen (Valencia, CA). 
Messenger RNA (mRNA) was DNase treated using TURBO DNase prior to 
generating complimentary DNA (cDNA) using reverse transcriptase (RT) 
following the manufacturer’s protocol. Quantitative PCR reactions were done 
using Brilliant III SYBR green detection of newly synthesized PCR products 
following manufacturer’s protocol. RT reactions were diluted 10 fold for each 
qRT-PCR reaction. Each qRT-PCR reaction had forward and reverse primers at 
a final concentration of 10M. Primers used for the qRT-PCR reactions are 
shown in Table 1. 
Electrical cell substrate impedance sensing (ECIS) 
ECIS was used to measure NHBE and Calu3 cell migration. Cells were 
grown on 8W1E ECIS arrays, maintained in complete growth media until fully 
confluent. Media was then changed to serum-free for 48 hours. A 250 m wound 
was produced by electroporation (6V, 30 kHz, 60 seconds) of cells in contact with 
the electrode. Cells were washed with PBS and treatment media was added. 
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Impedance was measured using an alternating current (~ 1A, 15 kHz) that was 
continuously applied to the electrodes. Wound closure was measured for each 
treatment by determining the time required to reach 50% of the maximum 
impedance. 
Lamellipodia Assay 
 A lamellipodia protrusion assay was performed using NHBE and Calu-3 
cells under the following treatment conditions: 10M epinephrine or 10M 
salbutamol, 20M CFTRinh-172, 20M CFTRinh-172 + 10M epinephrine and an 
untreated control condition. Chamber slides were coated with bovine collagen 
diluted in 0.01N acetic acid. Calu-3 cells were seeded on precoated slides and 
maintained using standard conditions and growth media until confluent. Cells 
were changed to SF media for 48 hours. Scratch wounds were made using a 
scalpel blade dipped in liquid N2; cells were washed in PBS and exposed to 
treatment conditions for 60 minutes. This treatment exposure time was previously 
shown to be sufficient for cells to produce lamellipodia and start the process of 
migration (Schiller, Maniak, O'Grady 2010). After an hour cells were washed and 
fixed with 3.7% paraformaldehyde for 10 minutes at room temperature then 
treated with 0.1% Triton X for 4 minutes. Cells were then blocked with 1% Bovine 
Serum Albumin for 20 minutes and stained with Texas-Red phalloidin stain (5 
U/ml) for 20 minutes. Images were taken using fluorescent microscopy. 
Lamellipodia pixel area was measured using ImageJ software (National Institutes 
of Health, Bethesda, MD) as previously described (Schiller, Maniak, O'Grady 
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2010) and the average lamellipodia area from each image was statistically 
analyzed.  
Statistical Analysis 
Statistical significance was determined using an unpaired, two-tailed t-test 
(for single comparisons) or an ANOVA followed by Dunnett's test for single 
comparisons between treatment conditions and a common untreated control. A 
value of p< 0.05 was considered significant. 
D. Results:  
 The effects of -AR agonists on epithelial cell migration was studied using 
ECIS after wounding cells with a 6V pulse for 60 seconds applied at a frequency 
of 30 kHz. The stages of migration and impedance changes after wounding are 
shown in figure 1A-C. Note that complete wound closure occurred in 300 minutes 
after wounding (Fig 1C). The normalized impedance increase over time is shown 
as a continuous line tracing and was found to be nearly linear for NHBE cells (Fig 
1D). The data points shown in figure 1D represent measurements of the 
fractional increase in area of the electrode that was covered by cells at specific 
time points during the 300 minute restitution period after wounding. This result 
indicated that continuous impedance measurements directly reflect the extent of 
cell confluence over the electrode surface over time.  
 Epithelial cells have been shown to express multiple -ARs and to 
respond to selective -AR agonists (Ghoghawala et al. 2008) Quantitative PCR 
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results shown in figure 2A and 2B demonstrates that both NHBE and hVE 
express -AR with the highest levels of expression for 1 and 2 receptors. The 
Ct value for the 3 receptor was >30 cycles in both NHBE and hVE cells, 
indicating relatively low levels of mRNA and protein expression relative to the 1 
and 2 subtypes. 
 In migration experiments treatment of NHBE cells with the pan specific -
AR agonist epinephrine caused an increase in the time it takes for complete 
wound closure to occur, and when treated with a 2 selective agonist 
(salbutamol) the time to complete wound closure was  increased more than what 
was observed with epinephrine (Fig. 3A). In contrast, when cells were treated 
with a 1 selective agonist (dobutamine), no significant change in migration was 
observed compared to untreated controls (Fig. 3B). Similar results were obtained 
for NE and dopamine when applied to hVE and hCE cells (Figs. 4A)  To 
quantitatively analyze the effects of 2-AR agonists on the migration behavior of 
the NHBE cells, measurements of the time required for the impedance to reach 
half maximal restitution (Z0.5) was measured and the results reported in figure 3C. 
Values for Z0.5 measurements were significantly increased in cells treated with 
epinephrine or salbutamol compared to untreated control conditions but this was 
not true for cells treated with dobutamine. Increases in time to wound closure for 
NE were also observed in hVE and hCE cells (Figs. 4C and 4D) and a 
comparable response to dopamine was recorded in hVE cells (Fig. 4C).  
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 The fractional confluence per hour in NHBE cells that were stimulated with 
epinephrine or salbutamol were significantly different when compared to 
untreated control cells, whereas no difference was observed in dobutamine 
treated cells. (Fig 3D). Furthermore, there was no significant difference between 
the epinephrine and salbutamol treated conditions. This finding indicated that 2-
AR agonists increased the time to complete wound closure by slowing the 
migration rate over the entire duration of the restitution process. Similarly, the 
initial rate (between 0 and 4 hrs) of restitution in hVE cells was significantly 
reduced in response to NE and dopamine, this was also true for hCE cells 
treated with NE. Interestingly, the biphasic effects of NE and dopamine in hVE 
cells indicate that migration rate is initially suppressed by -AR agonists, but then 
recovers to the control rate well before complete restitution is achieved (Figs. 
4A). In contrast, the effect of NE in hCE cells appears to produce a delay in the 
onset of migration but shortly after migration begins, the rate is comparable to the 
untreated control condition (Fig. 4B). The addition of NE in both hVE and hCE 
cells caused a significant delay in wound recovery time (Fig. 4C and D) which is 
also represented in the measurements of confluence per hour (Fig 4 E and F). 
To further establish the identity of the -AR subtype responsible for the 
effects of epinephrine on cell migration, a series of experiments were performed 
using -AR antagonists. Pretreatment of NHBE and hVE cells with 10M 
propranolol completely rescued the effect of epinephrine on migration (Figs. 5 
and 6) Analysis of the time required to reach half maximal restitution in NHBE 
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and hVE cells is presented in figures 5B and 6B. Additionally, we tested ICI-
118551, a 2 selective antagonist prior to epinephrine treatment. Figure 5A 
shows that ICI-118551 also rescues the effect of epinephrine on cell migration as 
well as the time to reach half maximal recovery (Figure 5B). 
 In Calu-3 cells the effect of Cl- replacement with methane sulfonic acid on 
cell migration was studied using ECIS. Figure 7A shows that Cl- replacement 
significantly decreases the rate of cell migration compared to control conditions. 
Also when cells are additionally treated with CFTRinh-172 no further effect on cell 
migration was observed. This result indicated that the Cl- replacement effect was 
dependent on the activity of CFTR. In order to further verify the pharmacological 
actions of CFTRinh-172 on CFTR function a CFTRinh-172 dose response 
relationship was determined and presented in 7B. The IC50 value was 3.91 M, 
consistent with inhibition of CFTR channel activity. In addition, figure 7C 
compares the effects of CFTR silencing by RNAi (Palmer et al. 2006) and 
CFTRinh-172 treated shALTR cells (cells expressing a non-CFTR targeting 
shRNA). Both conditions increased the time to reach complete restitution when 
compared to the shALTR cells alone. A summary of the Z0.5 values for Cl
- 
replacement, CFTRinh-172, and CFTR silenced cells showing significant 
increases in the time needed to achieve 50% restitution is presented in Figure 
7D. Moreover, chloride replacement conditions with or without CFTRinh-172 and 
CFTR silenced or CFTRinh-172 treated shALTR cells were all shown to have 
significantly decreased fractional confluence per hour compared to untreated 
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controls indicating that the overall rates of migration were slower and that the 
increase in the time required for restitution was not the result of a delay in the 
initiation of migration.  
The effects of pretreatment of NHBE cells with CFTRinh-172 with and 
without 10M epinephrine are presented in figure 8. The results show that cells 
treated with CFTRinh-172 alone exhibited the same delay in restitution as cells 
treated with CFTRinh-172 + epinephrine (Fig 8A). Similar results were obtained 
with CFTR silenced Calu-3 cells treated with 10M salbutamol. A statistical 
analysis of the Z0.5 values is reported in figure 8B. The observation that neither 
epinephrine nor salbutamol produced an additional reduction in cell migration 
following CFTR inhibition indicated that a reduction in CFTR activity over time 
was associated with chronic exposure to -AR agonists.  
 The effect of the -AR inverse agonist carvedilol on cell migration in NHBE 
and Calu-3 cells is presented in figure 9. In both cell systems carvedilol caused 
an increase in the required time for wound closure when compared to the 
untreated control condition and NHBE cells produced an effect similar to the 2-
AR agonist isotharine (Figure 9A and B). The time to half maximal restitution was 
significantly greater in cells treated with carvedilol and isotharine (Figure 9B). 
These findings indicate that G-protein activation in response to agonist binding is 
not required to reduce cell migration and that pathways associated with MAP 
kinase signaling or possibly 2-AR down-regulation are involved. Figure 10A and 
B show the effects of CFTR inhibition with CFTRinh-172 and 10M epinephrine or 
 76 
 
salbutamol on lamellipodia area in NHBE and Calu-3 cells. -agonist induced 
inhibition of cell migration was associated with a decrease in the extent of 
lamellipodia protrusion, this effect was similar to what was observed in cells 
treated with CFTRinh-172. 
 
E. Discussion 
 Previous studies have shown that 2-AR stimulation with isoproterenol 
leads to a decrease in migratory speed of both keratinocytes and corneal 
epithelial cells (Chen, Hoffman, Isseroff 2002; Ghoghawala et al. 2008; Pullar, 
Chen, Isseroff 2003) The authors reported that activation of the receptor resulted 
in dephosphorylation of extracellular signal-related kinase (ERK) and a decrease 
in the migration rate (Ghoghawala et al. 2008; Pullar, Chen, Isseroff 2003; Pullar 
et al. 2006). Stimulation of 2-AR in both keratinocytes and corneal epithelial cells 
produced an increase in protein phosphatase 2A (PP2A) activity. The effect -AR 
agonists have on migration and ERK phosphorylation was reversed when cells 
were pretreated with okadaic acid a PP2A inhibitor, suggesting that inhibition of 
migration was dependent on the PP2A pathway (Pullar, Chen, Isseroff 2003). It 
was later shown that treating cells with -AR antagonists produced an opposite 
effect on both keratinocytes and corneal epithelial cells, increasing the rate of 
wound repair and promoting ERK phosphorylation (Pullar, Rizzo, Isseroff 2006; 
Pullar et al. 2007). 
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  Although the effects of -AR stimulation have been well studied in 
keratinocytes and corneal epithelial cells, the effects of -AR stimulation on 
airway epithelial cell migration has not been extensively investigated. Results 
from the present study demonstrated that when NHBE and Calu-3 cells were 
stimulated with either epinephrine or salbutamol, a significant decrease in cell 
migration was observed. This effect however was not detected when cells were 
treated with a 1-AR agonist dobutamine. These results are consistent with 
previous findings in keratinocytes and corneal epithelium where the actions of 
epinephrine were also mediated through 2-ARs (Ghoghawala et al. 2008; Pullar, 
Chen, Isseroff 2003; Pullar et al. 2006). In studies performed by Pullar et al it was 
shown that -AR antagonists accelerated wound repair by increasing the 
phosphorylation state of ERK (Pullar, Rizzo, Isseroff 2006; Pullar et al. 2007). 
Experiments with NHBE and Calu-3 cells pretreated with the panspecific -AR 
antagonist propranolol or the 2-AR antagonist ICI-118551 and then stimulated 
with epinephrine also showed no decrease in the cell migration rate. This 
phenomenon was also shown in hVE and hCE cells, indicating that inhibitory 
regulation of cell migration following 2-AR stimulation is broadly observed in 
epithelial cells. 
 CFTR function was previously shown to be essential in the migration of 
airway epithelial cells (Schiller, Maniak, O'Grady 2010). Silencing the expression 
of CFTR or treating Calu-3 cells with CFTRinh-172, a CFTR inhibitor, produced a 
significant decrease in the rate of cell migration. Similarly, when Calu-3 cells 
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expressing a non-CFTR targeting shRNA were treated with CFTRinh-172 the 
effects on cell migration were comparable to CFTR silenced cells, causing 
delayed wound closure. To determine if the inhibitory effects of epinephrine on 
migration were linked to an effect on CFTR, experiments were conducted to 
establish whether inhibition of CFTR activity or protein expression would block 
any further decrease in migration evoked by epinephrine or salbutamol. The 
results indicated that the effects of epinephrine on migration were dependent on 
functional CFTR since no additive effects of -AR agonists on migration were 
observed. There are several ways in which epinephrine could affect the 
availability or function of CFTR in airway epithelial cells. Previous studies by 
Naren et al showed that 2-AR and CFTR are physically linked in the plasma 
membrane (Naren et al. 2003). It is known that epinephrine leads to Gs signaling 
causing an increase in cAMP production. (Benovic 2002; Han, Kommaddi, 
Shenoy 2013; Naren et al. 2003; Reiter and Lefkowitz 2006; Reiter et al. 2012; 
Shenoy et al. 2006; Shenoy and Lefkowitz 2011). This increase in cAMP 
production activates CFTR leading to Cl- secretion. We showed that when there 
is no Cl- transport, whether it is due to lack of Cl- in the medium or an inability to 
transport Cl-, for example due to limited expression or non-functional CFTR, a 
decrease in migration rate is observed. These results provide evidence that Cl- 
transport may play an important role in wound repair.  
 It is known that epithelial cells respond to electric fields (EF) caused by 
disruption (wounding) of the epithelium. Cells respond to this field by moving 
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toward the cathode at the center of the wound, thus the electric field acts as a 
guidance cue to direct cell migration in a process that is called electrotaxis 
(Chiang, Robinson, Vanable 1992; Song et al. 2002; Sun et al. 2011; Zhao et al. 
1996a; Zhao et al. 1996b). CFTR appears to play an essential role in producing 
this wound current and guidance cue, which affects lamellipodia protrusion 
(Schiller, Maniak, O'Grady 2010; Sun et al. 2011). Interestingly, measurements of 
lamellipodia area after treatment with salbutamol or epinephrine showed a 
significant decrease compared to the untreated control condition, which was 
nearly identical to the effect of CFTRinh-172 on lamellipodia area. These results 
support the hypothesis that chronic exposure to 2-AR agonists produce a 
decrease in CFTR function over the time course of the wound healing experiment 
and that this results in a reduced wound current and loss of directional control 
over the migration process. Previous studies reported in Chapter 2 of this thesis 
indicate that chronic exposure to carvedilol induces down-regulation of the 2-AR 
receptor and a decrease in the level of CFTR expression in the apical membrane 
of Calu-3 cells, which is also consistent with this hypothesis.  
 The effects of long acting 2-AR agonists have been shown to have 
increased negative effects with chronic use. These drugs are usually prescribed 
over the lifetime of individuals that suffer from obstructive airway disease (Kew, 
Dias, Cates 2014; Saguil and Garcia 2014) This pattern of drug use can lead to 
decreased effectiveness of -agonists on the airways which can increase the 
number of exacerbations as well as the severity of such symptoms (Page and 
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Spina 2006; Walker et al. 2011; Wasilewski, Lougheed, Fisher 2014). This 
evidence suggests a potential need for change in the use of 2-AR agonists in 
treating obstructive airway diseases and investigate other possibilities. Bias 
ligands are one potential solution for new drug therapies although their 
effectiveness for symptom relief in individuals suffering from an obstructive 
airway disease has not been greatly studied. Currently carvedilol, a 2-AR 
inverse bias ligand is used in patients with heart disease to promote vasodilation 
and decrease heart rate (Bristow et al. 1996; Kveiborg et al. 2007; Vanderhoff, 
Ruppel, Amsterdam 1998). Although inverse ligands have shown to be beneficial 
for cardiac patients, the use of them in the airways is limited. Treatment of NHBE 
or Calu-3 cells with carvedilol produces a significant decrease in rate of wound 
closure which is very similar to the effect of epinephrine or salbutamol. This effect 
on migration is likely due to a conformational change in the receptor preventing 
activation of Gs signaling and activating the -arrestin signaling pathway (Kim et 
al. 2008; Shenoy and Lefkowitz 2011; Wisler et al. 2007). This pathway, which 
has been discussed in Chapter 2, suggests that MARCH2, an ubiquitin ligase, is 
responsible for promoting internalization of the 2-AR-CFTR signaling complex 
(Han et al. 2012; Wisler et al. 2007). This would lead to a decrease in apical 
membrane CFTR expression and reduce the rate of cell migration during wound 
repair.  
 In summary, these experiments have shown that 2-AR stimulation leads 
to a significant decrease in the rate of cell migration of airway epithelial cells and 
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this effect is rescued when cells are pretreated with -AR antagonists. We 
hypothesize that epinephrine caused down-regulation of the 2-AR leading to a 
decrease in Gs signaling which slows migration speed and increases the time 
required for wound closure. We have also shown that treating cells with the 
inverse ligand carvedilol also reduces the rate of wound closure, consistent with 
down-regulation of the 2-AR signaling complex. The need for new drug 
development to treat the symptoms of individuals with obstructive airway disease 
with no negative impact on airway restitution is essential. Bias ligands may be 
the answer. A bias ligand that activates only the Gs signaling arm of GPCR would 
promote smooth muscle relaxation and CFTR activation. These drugs would 
avoid -arrestin dependent signaling, preventing the negative downstream 
effects on migration.  
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Table 1: Human primer sets used for qRT-PCR in NHBE cells.  
Primer Sequence (5'-3') 
GAPDH F TGGAAATCCCATCACCATCT 
GAPDH R TTCACACCCATGACGAACAT 
-Actin F TCCCTGGAGAAGAGCTACGA 
-Actin R AGCACTGTGTTGGCGTACAG 
1-AR F CAATGACACACAGGGTCTCG 
1-AR R CAGACGCTCACCAACCTCTT 
2-AR F TGCTATGCCAATGAGACCTG 
2-AR R TCCACCTGGCTAAGGTTCTG 
3-AR F TGACCAACGTGTTCGTGACT 
3-AR R GTTGGTCACAGCCAGGTAGC 
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Figure 1 
 
Figure 1: Impedance is a measure of cell coverage on electrodes during migration. Images of 
NHBE cells on electrodes at the different migration stages: A: Immediately after wounding; B: 200 
minutes and C: 300 minutes after wounding. D: Solid line: The averaged normalized impedance 
over time during wound closure from NHBE cells. Data points: Normalized fractional coverage of 
the electrode by the NHBE cells.  
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Figure 2 
 
Figure 2: 2-AR is the most prevalent -AR in NHBE and hVE cells A: QRT-PCR amplification 
plot showing relative fluorescence vs. Cycle number for hVE cells (n=6). B: QRT-PCR 
amplification plot showing relative fluorescence vs. Cycle Number for NHBE cells (n=6).  
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Figure 3 
 
Figure 3: Effects of -AR agonists on migration rate of NHBE cells. A: The averaged change in 
impedance relative to the maximum impedance (normalized impedance change) during wound 
closure of NHBE cells treated with vehicle (DMSO; black line, n=8), epinephrine (10M 
epinephrine + DMSO; red line, n=8) or salbutamol (10M salbutamol; blue line, n=8) B: The  
normalized impedance change during wound closure of NHBE cells treated with vehicle (DMSO; 
grey bar, n=8) or dobutamine (red line, n=8). C:  The averaged time to reach half maximal 
restitution of NHBE cells treated with vehicle (DMSO; grey bar, n=8), epinephrine (10M 
epinephrine + DMSO; pink bar, n=8), salbutamol (10M salbutamol; blue bar, n=8), control (grey 
bar, n=8) or dobutamine (10M dobutamine; red bar, n=8). D: The fractional confluence per hour 
of NHBE and Calu-3 cells treated with vehicle (DMSO; grey bar, n=8), epinephrine (10M 
epinephrine + DMSO; pink bar, n=8), salbutamol (10M salbutamol; blue bar, n=8), control (grey 
bar, n=8) or dobutamine (10M dobutamine; red bar, n=8).   
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Figure 4 
 
Figure 4: Effects of norepinephrine on migration rate of hVE and hCE cells. A: The averaged 
normalized impedance change during wound closure of hVE cells treated with control (black line, 
n=8), or norepinephrine (red line, n=8) B: The averaged normalized impedance change during 
wound closure of hCE cells treated with control (black line, n=8), or norepinephrine (red line, n=8) 
C: The averaged time to reach half maximal restitution of hVE cells treated with control (grey bar, 
n=8), norepinephrine (red bar, n=8) or dopamine (striped bar, n=8). D: The averaged time to 
reach half maximal restitution of hCE cells treated with control (grey bar, n=8), or norepinephrine 
(red bar, n=8) E: The fractional confluence per hour of hVE cells treated with control (grey bar, 
n=8) , norepinephrine (red bar, n=8) or dopamine (striped bar, n=8). F: The fractional confluence 
per hour of hCE cells treated with control (grey bar, n=8), or norepinephrine (red bar, n=8). 
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Figure 5 
 
Figure 5: Effects of -AR agonists and antagonists on migration rate of NHBE cells over time. A: 
The averaged normalized impedance change during wound closure of NHBE cells treated with 
vehicle (DMSO; black line, n=4), epinephrine (10M epinephrine + DMSO; red line, n=5) 
propranolol + epinephrine (10M propranolol + 10M epinephrine + DMSO; blue line, n=6) or ICI-
118551 + epinephrine (1M ICI + 10M epinephrine; green line, n=4). B: The averaged time to 
reach half maximal restitution of NHBE cells treated with vehicle (DMSO; grey bar, n=4) 
epinephrine (10M epinephrine + DMSO; red bar, n=5), salbutamol (salbutamol; purple bar, n=8) 
propranolol + epinephrine (10M propranolol + 10M epinephrine + DMSO; blue bar, n=6) or ICI-
118551 + epinephrine (1M ICI + 10M epinephrine; green bar, n=4). C: The fractional 
confluence per hour of NHBE cells treated with vehicle (DMSO; grey bar, n=4) epinephrine (10M 
epinephrine + DMSO; red bar, n=5), salbutamol (salbutamol; purple bar, n=8) propranolol + 
epinephrine (10M propranolol + 10M epinephrine + DMSO; blue bar, n=6) or ICI-118551 + 
epinephrine (1M ICI + 10M epinephrine; green bar, n=4). 
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Figure 6  
 
Figure 6:  Effects of -AR agonists and antagonists on migration rate of hVE cells over time. A: 
The averaged normalized impedance change during wound closure of hVE cells treated with 
control (black line, n=10), epinephrine (10M epinephrine; red line, n=11) or propranolol + 
epinephrine (10M propranolol + 10M epinephrine; blue line, n=10). B: The averaged time to 
reach half maximal restitution hVE cells treated with control (grey bar, n=10), epinephrine (10M 
epinephrine; red bar, n=11) or propranolol + epinephrine (10M propranolol + 10M epinephrine; 
blue bar, n=10). C: The fractional confluence per hour of hVE cells treated with control (grey bar, 
n=10), epinephrine (10M epinephrine; red bar, n=11) or propranolol + epinephrine (10M 
propranolol + 10M epinephrine; blue bar, n=10). 
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Figure 7 
 
Figure 7:  The importance of CFTR on the migration rate of Calu-3 cells. A: The averaged 
normalized impedance change during wound closure of Calu-3 cells treated with vehicle (DMSO; 
black line, n=4), chloride free media (DMSO; blue line, n=10), or chloride free with CFTR inh-172 
(20M CFTRinh-172; red line, n=5). B: The averaged normalized impedance change over time of 
a dose response to CFTRinh-172 in Calu-3 cells. C: The averaged normalized impedance over 
time during wound closure of Calu-3 ALTR cells (DMSO; black line, n=7), shCFTR Calu-3 cells 
(DMSO; blue line, n=4) or Calu-3 ALTRs with CFTRinh-172 (20M CFTRinh-172; red line, n=8). D: 
The averaged time to reach half maximal restitution of Calu-3 treated with vehicle (DMSO; light 
grey bar, n=4), chloride free media (DMSO; light blue bar, n=10), chloride free with CFTR inh-172 
(20M CFTRinh-172; pink bar, n=5), Calu-3 ALTR cells (DMSO; striped bar, n=7), shCFTR Calu-3 
cells (DMSO; blue bar, n=4) or Calu-3 ALTRs with CFTRinh-172 (20M CFTRinh-172; red bar, 
n=8).E: The fractional confluence per hour of Calu-3 treated with vehicle (DMSO; light grey bar, 
n=4), chloride free media (DMSO; light blue bar, n=10), chloride free with CFTRinh-172 (20M 
CFTRinh-172; pink bar, n=5), Calu-3 ALTR cells (DMSO; dark grey bar, n=7), shCFTR Calu-3 cells 
(DMSO; blue bar, n=4) or Calu-3 ALTRs with CFTRinh-172 (20M CFTRinh-172; red bar, n=8).   
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Figure 8 
 
Figure 8:  Effects of epinephrine or salbutamol on Calu-3 that were pretreated with CFTRinh-172 
or CFTR silenced. A: The averaged normalized impedance change during wound closure of 
Calu-3 cells treated with vehicle (DMSO; black line, n=8), CFTRinh-172 (20M CFTRinh-172; blue 
line, n=8) or CFTRinh-172 + epinephrine (20M CFTRinh-172 + 10M epinephrine; red line, n=8). 
B: The averaged time to reach half maximal restitution of NHBE treated with vehicle (DMSO; grey 
bar, n=8), CFTRinh-172 (20M CFTRinh-172; red bar, n=8), CFTRinh-172 + epinephrine (20M 
CFTRinh-172 + 10M epinephrine; green bar, n=8) shALTR cells treated with vehicle (DMSO; grey 
bar, n=6), and shCFTR cells treated with vehicle (DMSO; grey bar, n=7), shALTR cells treated 
with salbutamol (10M salbutamol; blue bar, n=6), shCFTR cells treated with salbutamol (10M 
salbutamol; blue bar, n=6). 
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Figure 9 
 
Figure 9: Effects of -AR inverse ligands on migration rate of Calu-3 and NHBE cells over time. 
A: The averaged normalized impedance change during wound closure of NHBE cells treated with 
vehicle (DMSO; black line, n=6), carvedilol (10M carvedilol; red line, n=8) or isoetharine (10M 
isoetharine; blue line, n=7). B: The averaged time to reach half maximal restitution of Calu-3 and 
NHBE cells treated with vehicle (DMSO; grey bar, NHBE n=6 and Calu-3 n=11), carvedilol (10M 
carvedilol; pink bar, NHBE n=8 and Calu-3 n=9) or isoetharine (10M isoetharine; blue bar, n=7).  
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Figure 10 
 
 
Figure 10: Effects of epinephrine and salbutamol on lamellipodia protrusion in NHBE and Calu-3 
cells. A: An image of lamellipodia protrusion in control (top) and epinephrine treated (bottom) 
cells. B: Average pixel area of lamellipodia per NHBE cell treated with vehicle (DMSO; grey bar, 
n=6 fields), epinephrine (10M epinephrine + DMSO; pink bar, n=5 fields) or CFTRinh-172 (blue 
bar, n=5 fields) and Calu-3 cells treated with vehicle (DMSO; grey bar, n=5 fields) and 10M 
salbutamol (red bar, n=4 fields). 
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A. Conclusion of Thesis: 
 Previous studies have shown the importance of CFTR  and 2-AR 
agonists on the migration of  airway epithelial cells (Chen, Hoffman, Isseroff 
2002; Pullar et al. 2006; Pullar et al. 2007; Schiller, Maniak, O'Grady 2010; Sun 
et al. 2011). Although 2-AR agonists are effective in providing symptom relief in 
individuals with obstructive airway disease these drugs have been shown to 
decrease the ability of the airway epithelium to effectively repair itself following 
injury (Cockcroft and Sears 2013; Page and Spina 2006; Spina 2014). These 
studies showed that since the introduction of inhaled -AR agonists there have 
been problems in determining the most effective dose with least amount of risk 
(Cockcroft and Sears 2013; Page and Spina 2006). In the 1960s some countries 
such as the United Kingdom and Australia were using an increased dose of 
isoproteranol compared to the United States and it was shown that the use of this 
inhaled non-specific -AR agonist increased the number of asthma related 
deaths (Cockcroft and Sears 2013; Page and Spina 2006). This was seen again 
in New Zealand with fenoterol a short acting  agonist and in 2000 the 
Salmeterol Multicenter Asthma Research Trial (SMART) showed the use of 
salmeterol lead to an increase in asthma mortality (Cockcroft and Sears 2013; 
Nelson et al. 2006; Page and Spina 2006). It is suggested that the chronic use of 
-AR agonists causes an increase in medication tolerance, responsiveness of 
the airways to allergins, and inflammation. It is also thought that when these 
medications are used, they alleiviate the initial asthmaic episode leading to 
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inflammation masking of the later stages of the asthmatic response which 
potentially leads to increased inflammation and epithelial damage over time 
(Cockcroft and Sears 2013; Page and Spina 2006). The continual damage to the 
airway over time is thought to be the culprit of -AR agonist related deaths. 
1. Adrenergic receptors and mucociliary clearance 
 Earlier studies by Naren et al. (2003) showed that apical 2 ARs are 
coupled to CFTR by adapter proteins that form a scaffold for PKA, ensuring that 
the cAMP-dependent  kinase is positioned in close proximity to phosphorylation 
sites within the regulatory domain of CFTR (Figure 1). 
 
Figure 1 
2-AR-CFTR signaling complex 
 
Figure 1: A model of the CFTR-2-AR signaling complex connected by adapter proteins 
NHERF1, EZRIN and PKA in the apical membrane. 
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Data presented in Chapter 3 showed that stimulating 2-ARs on the apical 
membrane with epinephrine produces an initial increase in anion secretion that is 
then significantly diminished after continuous agonist exposure. Stimulation of 
the receptor with epinephrine leads to the activation of G-protein signaling, 
generation of cAMP and subsequent activation of PKA. This kinase then 
phosphorylates CFTR causing the channel to open and allowing Cl-  to exit the 
cell across the apical membrane. With continuous agonist exposure however, 
phosphorylation of the receptor by GRK occurs, which facilitates binding of -
arrestin and down-regulation of the receptor. Biotynylation experiments in 
chapter 2 revealed that 2-AR disappearance from the apical membrane is nearly 
complete within 30 minutes of continuous treatment with epinephrine or 
carvedilol. 2-AR desensitization is thought to be responsible for the decrease in 
anion secretion that occurs with increasing time of agonist exposure. Previous 
studies have shown that activation of -arrestin signaling after agonist binding 
leads to downstream signaling through MAPK activation as well as recruitment of 
Nedd4 an E3 ubiquitin ligase responsible for ubiquitination of proteins to promote 
protein trafficking to lysosomes (Han, Kommaddi, Shenoy 2013; Shenoy et al. 
2008; Shenoy and Lefkowitz 2011). However once the receptor is internalized, 
deubiquitinases (USP20 and USP33) can associate with the 2-AR and prevent 
degradation by deubiquinating the receptor, promoting receptor recycling 
(Berthouze et al. 2009; Han, Kommaddi, Shenoy 2013). Furthermore studies 
have shown that cAMP production after a 2-agonist binds to the 2-AR leads to 
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CFTR activation and phosphorylation of CFTR which is thought to cause the 2-
AR-CFTR signaling complex to dissociate (Naren et al. 2003). Thus the 2-AR 
and CFTR are internalized and recycled or degraded separately.  
 When the 2-AR was stimulated with the inverse ligand carvedilol, the 
immediate response was different from the effect observed with epinephrine. 
Carvedilol stimulation caused a decrease in basal CFTR-dependent anion 
secretion, consistent with an inverse ligand (Parra and Bond 2007), initiated 
conformational change of the receptor that promotes -arrestin signaling while 
preventing Gs mediated signaling (Andresen 2011; Han et al. 2012; Kim et al. 
2008; Kim et al. 2005; Shenoy and Lefkowitz 2011; Wisler et al. 2007). This 
leads to desensitization of the receptor (Tilley 2011) which in turn would 
decrease the ability of CFTR to be activated through 2-AR activation. Figure 2 
shows pathways that are activated by either epinephrine or carvedilol binding to 
the 2-AR.  
 Note that epinephrine activates both G-protein and -arrestin signaling 
pathways. In contrast, carvedilol does not activate G-protein signaling, but does 
activate -arrestin mediated receptor desensitization and activation of MAPK 
dependent signaling. By blocking Gs signaling carvedilol prevents USP20 and 
USP33 from being activated therefore preventing the ability for the receptor to be 
deubiquinated and targeted for recycling (Berthouze et al. 2009; Han et al. 2012). 
Furthermore it has been shown that carvedilol blocks 2-AR association with 
Nedd4 (Han et al. 2012; Wisler et al. 2007). Instead the receptors associate with 
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MARCH2 another E3 ubiquitin ligase that is recruited and activated upon 
carvedilol binding (Han et al. 2012) (figure 3). This E3 ligase also promotes 
receptor targeting to lysosomes resulting in degradation (Han et al. 2012; Wisler 
et al. 2007).  
Figure 2 
G protein and -arrestin signaling  
 
Figure 2: Effects of 2-AR stimulation with epinephrine or carvedilol on signaling pathways. 2-AR 
causes G-Protein disassociation, activation of adenylyl cyclase leading to the production of 
cAMP. G-Protein Receptor Kinase (GRK) phosphorylates the C-termial tail of the receptor 
recruiting -arrestin which promotes internalization and initiation of additional signaling molecules. 
Carvedilol blocks G-Protein dissociation and promotes -arrestin signaling. 
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Figure 3 
Carvedilol effects on 2-AR signaling 
 
Figure 3: The effects of carvedilol after binding to the 2-AR involves, blocking Gs signaling, 
inhibitng Nedd4 and USP20 and USP30 activation, initiating -arrestin signaling, and triggering 
endocytosis via MARCH2 ligase. 
 
 An important result from chapter 2 was the observation that within minutes 
following treatment with carvedilol, basal anion secretion was inhibited and over 
a time period of 30 minutes, CFTR expression in the plasma membrane 
decreased by nearly 60% whereas epinephrine did not significantly alter the level 
of channel expression in the apical membrane over the same time period. The 
short-term response to carvedilol was likely due to inhibition of Gs-dependent 
signaling that results from the conformation change that occurs in the 2-AR  
induced by carvedilol. In addition this change in receptor conformation may also 
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prevent uncoupling of the 2-AR-CFTR signaling complex, suggesting the 
possibility that desensitization involves retreval of both 2-AR and CFTR together 
from the apical membrane (Figure 4). As previously mentioned, uncoupling of 
CFTR from the 2-AR appears to be dependent upon CFTR phosphorylation by 
PKA, therefore inhibition of Gs-signaling and dephosphorylation of the channel by 
PP2A could preseve NHERF-mediated scaffolding interactions between the two 
proteins as shown in Figure 1. 

Figure 4 
2AR-CFTR signaling complex in airway epithelial cells 
  
Figure 4: 2-AR-CFTR signaling complex located in the apical membrane of airway epithelial cells 
is internalized after 2-AR stimulation with carvedilol. 
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2. Adrenergic regulation of airway epithelial cell migration and wound repair 
 It has been previously suggested that -agonists activate ERK-dependent 
signaling in HEK293 (human embryonic kidney cells), COS-7 cells (monkey 
fibroblast like cells) and cardiac myocytes studying cardiac hypertrophy (Schmitt 
and Stork 2000; Zou et al. 2001). These studies showed that treating cells with 
isoproterenol leads to 2-AR activation resulting in ERK phosphorylation which 
was blocked with alpreolol a -AR antagonist (Schmitt and Stork 2000). It is also 
known that ERK activation can promote cell migration which has been shown in 
osteoblasts and fibrosarcoma cells (Lai et al. 2001; Webb, Nguyen, Gonias 
2000). Studies used dominate negative mutants of ERK as well as ERK inhibitors 
to show that ERK is important in migration, both the dominant negative mutant 
and cells treated with ERK inhibitors blocked cell migration (Lai et al. 2001).  
 As previously stated ERK plays an important role in cell migration, and 
does so by interacting with several other proteins involved in the protrusion, 
adhesion and retraction processes of migration. Myosin light chain kinase 
(MLCK) is one of these proteins. It has been shown that ERK is important in the 
activation of MLCK and MLC which play a role in the turnover of focal adhesions 
and protrusions at the leading edge of migrating cell (Huang, Jacobson, Schaller 
2004). Calpins, Ca2+ activated enzymes, are also activated by ERK in low 
calcium conditions, and are important in focal adhesion disassembly and 
cytoskeletal changes needed for cell migration such as trailing edge detachment 
from ECM and leading edge protrusions (Campbell and Davies 2012; Huang, 
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Jacobson, Schaller 2004). Focal adhesion kinases (FAKs) also are important in 
cell migration. Studies have shown that FAKs are important in the 
phosphorylation of paxillin-kinase linker proteins which are known to interact with 
paxillin, promoting focal adhesion stimulation and cell polarity both of which are 
important in the process of migration (Yu, Deakin, Turner 2010) and ERK is 
responsible for their activation as well as the activation of FAK-Paxillin 
association (Huang, Jacobson, Schaller 2004). It has recently been shown that 
ERK is also responsible for phosphorylating histone deacetylase 6, a migration 
promoter that associates with microtubules and causes deacetylation of them 
playing a role in cell migration (Williams et al. 2013).  
 In contrast to the earlier findings that -agonist isoproterenol activates 
ERK, more recent studies using keratinocytes and corneal epithelial cells showed 
that stimulating 2-ARs with isoproterenol caused a decrease in the rate of 
migration due to the inhibition of ERK (Chen, Hoffman, Isseroff 2002; 
Ghoghawala et al. 2008; Han et al. 2012; Pullar, Chen, Isseroff 2003; Pullar et al. 
2006). This inhibition is caused by the activation of PP2A via 2-AR stimulation, 
which promotes the dephosphorylation of ERK (Ghoghawala et al. 2008; Pullar, 
Chen, Isseroff 2003; Pullar et al. 2006). As previously discussed the role of ERK 
is important in the migratory ability of cells through its role in the activation of 
proteins like MLCK, calpin, paxillin and FAK (Campbell and Davies 2012; Huang, 
Jacobson, Schaller 2004; Yu, Deakin, Turner 2010). The results presented in 
chapter 3 of this thesis were consistent with previous studies in keratinocytes and 
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corneal epithelia, showing that migration was significantly slowed in airway 
epithelial cells, vaginal epithelial cells and cervical epithelial cells when the 2-AR 
was stimulated with epinephrine, salbutamol, carvedilol or norepinephrine. 
Interestingly, the effect of epinephrine on the migration rate in airway epithelial 
cells was dependent on the activity of CFTR. This conclusion was based on the 
observation that inhibition of CFTR activity with CFTRinh-172 or silencing mRNA 
expression of the channel blocked further reductions in the rate of epithelial 
restitution following the addition of -agonists. Moreover, treatment with 
salbutamol or epinephrine produced nearly identical reductions in lamellipodia 
area as observed after treatment with CFTRinh-172. These findings suggest that 
at least a portion of the inhibitory response to 2-AR stimulation in airway 
epithelial cells is related to a loss of the electrotactic guidance cue that occurs 
when the wound current is blocked in response to loss of CFTR function. Other 
mechanisms may also contribute and are discussed below.  
 One explanation for the reduction in CFTR function associated with 
carvedilol stimulation is the internalization of the 2-AR and CFTR upon 2-AR 
stimulation. This effect occurs early (within 30 min) in the time course for 
epithelial restitution and would be expected to cause inhibition of restitution 
comparable to the effect of a CFTR inhibitor, or partial mRNA silencing and 
reduced apical membrane expression. However, there is still residual CFTR in 
the apical membrane, thus it is possible that other mechanisms besides reduced 
CFTR function contributes to inhibition of migration, especially for epinephrine 
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which did not reduce the level of CFTR expression in the apical membrane, and 
as previously mentioned in this thesis the activation of 2-AR with epinephrine 
leads to -arrestin recruitment, which in turn promotes receptor internalization. 
This internalization would potentially lead to a decrease in CFTR activation due 
to the decrease in available cAMP which is generated through 2-AR activation 
and is essential in the activation of PKA. Previous studies in the keratinocytes 
and cornea have shown that  2-AR agonists like epinephrine are able to recruit 
PP2A, a serine/threonine protein phosphatase through the -arrestin signaling 
pathway (Pullar, Chen, Isseroff 2003; Reiter and Lefkowitz 2006). It has also 
been shown that PP2A and CFTR are found in the same complex (Vastiau et al. 
2005) and PP2A dephosphorylates CFTR causing the channel to become 
deactivated (Thelin et al. 2005; Vastiau et al. 2005). Furthermore recruitment of 
PP2A dephosphorylates ERK, an important player in cell migration, decreasing 
its activity (Janssens and Goris 2001; Pullar, Chen, Isseroff 2003), potentially 
aiding in the decrease in migration seen in airway epithelial cells like what has 
been shown in keratinocytes and corneal epithelial cells. Recruitment and 
activation of PP2A may represent an additional mechanism underlying the 
inhibitory effect of 2-AR stimulation on airway epithelial cell migration and wound 
repair. 
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B. Future directions: 
 Although the data in this thesis provides new insights on 2-AR receptor 
regulation of airway epithelial cell migration and anion secretion, the mechanisms 
responsible for these effects are not fully understood. To examine the possibility 
that 2-AR activation leads to PP2A recruitment and inhibition of CFTR function, 
experiments could be performed to determine the phosphorylated state of CFTR 
after treating with a 2-AR agonists. These experiments would determine if 
stimulating the 2-AR with an agonist or bias ligand causes CFTR 
dephosphorylation over time and if this correlates with changes in ion channel 
activity. This study would be done by isolating biotinylated proteins from the 
apical surface of NHBE or Calu-3 cells before and after -agonist treatment. 
Total CFTR protein would be identified by western blot analysis and the blot 
reprobed using phosphoantibodies that target specific phosphorylated states of 
the channel. This would establish if 2-AR stimulation decreases the activity of 
CFTR via dephosphorylation. It is predicted that -agonists cause a decrease in 
CFTR phosphorylation through the activation of PP2A. The effects of PP2A 
blockers like okadaic acid or cantharidine, and the effects of PP2A silencing 
could be used to see if the phosphorylated effects seen with -agonists are 
rescued. This would help determine if PP2A is responsible for the 
dephosphorylation of CFTR which in turn causes a decrease in cell migration. It 
is suggested that PP2A silenced cells and cells treated with PP2A blocker would 
have similar concentrations of phosphorylated CFTR protein as the control cells. 
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 Another experiment would be to measure the effects 2-AR stimulation 
has on PP2A recruitment to the 2-AR-CFTR signaling complex in the apical 
membrane. This could be accomplished by performing a pull-down assay, using 
antibodies against CFTR to immunoprecipitate the proposed PP2A-CFTR 
complex before and after -agonist stimulation. A western blot would then be 
performed, probing with a PP2A antibody. This could be used to quantitate the 
relative amount of PP2A associated with CFTR following 2AR activation and 
how this corresponds to the phosphorylation state of CFTR. Another experiment 
would be to examine the effect of PP2A on migration of airway epithelial cells. 
This could be done by stimulating the cells with epinephrine in the presence of a 
PP2A inhibitor to see if the inhibitory effect on migration is blocked in absence of 
functional PP2A. It is suggested that PP2A inhibitor will at least partially rescue 
the effect epinephrine has on cell migration bringing the migration rate near 
untreated control cells.   
 The findings of this thesis help advance the study of obstructive airway 
disease at the cellular level. These studies provide evidence that common 
treatments like albuterol or salmeterol have negative effects on the airway 
epithelium by decreasing CFTR activity and availability, leading to decreased 
efficiency and ability in wound repair and mucociliary processes. These can 
cause an increased potential for inflammation and damage to the airways which 
can lead to exacerbated problems in the later stages of disease. With future 
studies the ability to identify the mechanism(s) by which these issues occur will 
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be important in establishing new therapies, drug targets and drug development 
that are aimed to promote dilation of the airways while preventing CFTR 
deactivation, and therefore promote mucociliary and repair mechanisms.  
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